Variant rnai against alpha-synuclein
Variant RNAi molecules targeting alpha-synuclein with a loop structure address off-target silencing issues, effectively reducing alpha-synuclein expression and offering neuroprotection in neurodegenerative diseases.
Patent Information
- Application Number
- JP2024115452
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2018-08-03
- Filing Date
- 2024-07-19
- Publication Date
- 2024-11-06
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current RNAi therapies for neurodegenerative diseases like Parkinson's disease face challenges due to off-target silencing, which occurs when the RNAi seed region pairs with non-target mRNA sequences, leading to unintended transcriptional destabilization.
Development of variant RNAi molecules targeting alpha-synuclein (SNCA) with specific guide and non-guide regions, connected by an RNA linker forming a loop structure, to reduce off-target silencing and enhance specificity.
The variant RNAi molecules effectively reduce alpha-synuclein expression, providing neuroprotection and potentially halting the progression of neurodegenerative diseases by minimizing unintended gene silencing.
Smart Images

Figure 2024156715000006 
Figure 2024156715000007 
Figure 2024156715000008
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of priority to U.S. Provisional Application No. 62 / 714,616, filed August 3, 2018, which is incorporated by reference herein in its entirety.
[0002] Submitting a sequence listing as an ASCII text file The contents of the following submission in an ASCII text file are incorporated herein by reference in their entirety: Sequence Listing Computer Readable Form (CRF) (Filename: 159792016540SEQLIST.TXT, Date Recorded: July 31, 2019, Size: 19KB).
[0003] The present disclosure relates to variant RNAi molecules. In some embodiments, the present disclosure relates to variant RNAi molecules against alpha-synuclein. [Background technology]
[0004] Long-term neuroprotective therapy has gained considerable interest as a treatment for neurodegenerative synucleinopathies such as Parkinson's disease or multiple system atrophy (MSA). RNA interference (RNAi) is a mechanism by which target mRNA is reduced by introducing RNA (siRNA) that is complementary to the target. siRNA sequences are also inserted into artificial miRNA scaffolds ("shmiRNAs") that allow for constitutive, polymerase II-based expression while also eliminating the neurotoxicity associated with the introduction of siRNA or shRNA in the brain (1).
[0005] An obstacle to the clinical development of RNAi is the possibility of off-target silencing, where the seed region of RNAi (typically nucleotides 1-7 or 1-8) pairs with sequences of non-target mRNAs in the 3' untranslated region (UTR), causing transcriptional destabilization. Attempts to reduce off-target silencing include the use of algorithms to identify candidate seed sequences with high specificity for target mRNAs with minimal potential off-targets (Non-Patent Document 1) and the placement of an internal bulge in the guide region of RNAi (Non-Patent Document 2). [Prior art documents] [Non-patent literature]
[0006] [Non-Patent Document 1] Boudreau RL et al. (2012) Nucl. Acids Res. 41(1):e9 page [Non-Patent Document 2] Terasawa et al. (2011) Journal of nucleic acids 2011:131579 pages Summary of the Invention [Problem to be solved by the invention]
[0007] Multiple lines of evidence demonstrate that elevated levels of alpha-synuclein (SNCA) are neurotoxic, whereas their reduction is neuroprotective (2-9). Therefore, therapeutic strategies that reduce SNCA levels could potentially halt the progression of neurodegenerative diseases and alleviate their symptoms. There remains a need for such therapeutic strategies that utilize RNAi mechanisms. [Means for solving the problem]
[0008] The present application relates to variant RNAi molecules against SNCA and the treatment and This need is met by providing methods for its use in prevention.The present application also provides methods for screening or identifying RNAi molecules against SNCA and constructs for preparing these RNAi molecules.
[0009] In some aspects, the present invention provides an RNAi comprising a first strand and a second strand, a) the first strand and the second strand form a duplex; b) the first strand comprises a guide region, the guide region comprises a nucleic acid having at least about 90% identity to the sequence 5'-UGCUCUUUGGUCUUCUCAGCC-3' (SEQ ID NO:24) or at least about 90% identity to the sequence 5'-UGGGCACAUUGGAACUGAGCA-3' (SEQ ID NO:8); and c) the second strand comprises a non-guide region. In some embodiments, the guide region comprises the nucleic acid sequence 5'-UGCUCUUUGGUCUUCUCAGCC-3' (SEQ ID NO:24), and the non-guide region comprises the sequence 5'-GGCUGAGAACCAAAGAGUA-3' (SEQ ID NO:53). In some embodiments, the first strand comprises a nucleic acid sequence having about 90% identity to SEQ ID NO:24 or about 90% identity to SEQ ID NO:53. In some embodiments, the guide region comprises the nucleic acid sequence 5'-UGGGCACAUUGGAACUGAGCA-3' (SEQ ID NO:8) and the non-guide region comprises the sequence 5'-UGCUCAGUCAAUGUGCCUA-3' (SEQ ID NO:37). In some embodiments, the second strand comprises a nucleic acid sequence having about 90% identity to SEQ ID NO:37 or about 90% identity to SEQ ID NO:37. In some embodiments, the first strand and the second strand are linked by an RNA linker capable of forming a loop structure. In some embodiments, the RNA linker comprises 4 to 50 nucleotides. In some embodiments, the loop structure comprises 4 to 20 nucleotides. In some embodiments, the RNAi comprises, from 5' to 3', the second strand, the RNA linker, and the first strand. In some embodiments, the RNAi comprises, from 5' to 3', the first strand, the RNA linker, and the second strand. In some embodiments, the RNAi comprises the nucleic acid sequence of SEQ ID NO:61 or SEQ ID NO:63. In some embodiments, the RNAi comprises a nucleotide sequence that is about 90% identical to the nucleotide sequence of SEQ ID NO:61 or SEQ ID NO:63.In some embodiments, the RNAi is a small inhibitory RNA (siRNA), microRNA (miRNA), or a small hairpin RNA (shRNA).
[0010] In some embodiments of the above aspects and embodiments, RNAi targets RNA that codes for a polypeptide associated with neurodegenerative synucleinopathies.In some embodiments, the polypeptide is alpha-synuclein (SNCA).In some embodiments, the alpha-synuclein is human alpha-synuclein.In some embodiments, the neurodegenerative synucleinopathies are Parkinson's disease (PD), multiple system atrophy (MSA) or dementia with Lewy bodies (DLB).
[0011] In some embodiments of the above aspects and embodiments, the present invention provides an expression construct comprising a nucleic acid encoding an RNAi as described herein. In some embodiments, the nucleic acid encoding the RNAi comprises a miRNA scaffold. In some embodiments, the nucleic acid encoding the RNAi is operably linked to a promoter. In some embodiments, the promoter is a cytomegalovirus (CMV) immediate early promoter, RSV LTR, MoMLV LTR, phosphoglycerate kinase-1 (PGK) promoter, simian virus 40 (SV40) promoter, CK6 promoter, transthyretin promoter (TTR), TK promoter, tetracycline responsive promoter (TRE), HBV promoter, hAAT promoter, LSP promoter, chimeric liver specific promoter (LSP), E2F promoter, telomerase (hTERT) promoter; cytomegalovirus enhancer / chicken beta-actin / rabbit beta-globin promoter (CAG) promoter, elongation factor 1-alpha promoter (E The promoter is selected from the group consisting of a human β-glucuronidase promoter, a chicken β-actin (CBA) promoter, a retroviral Rous sarcoma virus (RSV) LTR promoter, a dihydrofolate reductase promoter, and a 13-actin promoter. In some embodiments, the expression construct further comprises an intron. In some embodiments, the intron is a CBA intron or a hEF1 alpha intron. In some embodiments, the intron is a chimeric intron. In some embodiments, the expression vector is a self-complementary vector and the intron is a delta-chimeric intron. In some embodiments, the expression construct further comprises a polyadenylation signal. In some embodiments, the polyadenylation signal is a bovine growth hormone polyadenylation signal, an SV40 polyadenylation signal, or an HSV TK polyadenylation signal.
[0012] In some embodiments, the present invention provides a vector comprising any of the expression constructs described herein. In some embodiments, the vector is a recombinant adeno-associated virus (rAAV) vector. In some embodiments, the expression construct is flanked by one or more AAV inverted terminal repeat (ITR) sequences. In some embodiments, the expression construct is flanked by two AAV ITRs. In some embodiments, the AAV ITRs are AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAVrh8, AAVrh8R, AAV9, AAV10, AAVrh10, AAV11, AAV12, AAV2R471A, AAV DJ, caprine AAV, bovine AAV, or mouse AAV serotype ITRs. In some embodiments, the AAV ITRs are AAV2 ITRs. In some embodiments, the vector further comprises a stuffer nucleic acid. In some embodiments, the stuffer nucleic acid is located upstream or downstream of the nucleic acid encoding RNAi.In some embodiments, the vector is a self-complementary rAAV vector.In some embodiments, the vector comprises a first nucleic acid sequence encoding RNAi and a second nucleic acid sequence encoding the complement of said RNAi, and the first nucleic acid sequence can form intrastrand base pairs with the second nucleic acid sequence over most or all of its length.In some embodiments, the first nucleic acid sequence and the second nucleic acid sequence are linked by a mutated AAV ITR, and the mutated AAV ITR comprises a deletion of D region and comprises a mutation of terminal resolution sequence.
[0013] In some embodiments, the invention provides a cell comprising any of the rAAV vectors described herein.
[0014] In some embodiments, the invention provides a recombinant AAV particle comprising any of the rAAV vectors described herein. In some embodiments, the AAV viral particle comprises an AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAVrh8, AAVrh8R, AAV9, AAV10, AAVrh10, AAV11, AAV12, AAV2R471A, AAV2 / 2-7m8, AAV DJ, AAV2 N587A, AAV2 E548A, AAV2 N708A, AAV V708K, AAV2-HBKO, AAVDJ8, AAVPHP.B, AAVPHP.eB, AAVBR1, AAVHSC15, AAVHSC17, caprine AAV, AAV1 / AAV2 chimera, bovine AAV, or mouse AAV capsid rAAV2 / HBoV1 serotype capsid. In some embodiments, ITR and the capsid of rAAV virus particle are derived from the same AAV serotype.In some embodiments, ITR and the capsid of rAAV virus particle are derived from different AAV serotypes.In some embodiments, ITR is derived from AAV2 and the capsid of rAAV particle is derived from AAV1.
[0015] In some embodiments, the invention comprises any of the rAAV particles described herein. Compositions are provided. In some embodiments, the composition further comprises a pharma- ceutically acceptable carrier.
[0016] In some embodiments, the present invention provides a kit comprising any of the RNAi described herein.In some embodiments, the present invention provides a kit comprising any of the AAV particles described herein.In some embodiments, the present invention provides a kit comprising any of the compositions described herein.In some embodiments, the kit further comprises instructions for use.
[0017] In some aspects, the present invention provides a method for treating a neurodegenerative synucleinopathic disease in a mammal, comprising administering to the mammal an RNAi comprising a first strand comprising a first nucleic acid having at least about 90% identity to the sequence 5'-UGCUCUUUGGUCUUCUCAGCC-3' (SEQ ID NO:24) or a first strand comprising a first nucleic acid having at least about 90% identity to the sequence 5'-UGGGCACAUUGGAACUGAGCA-3' (SEQ ID NO:8) and a second strand comprising a second nucleic acid. In some embodiments, the second nucleic acid comprises a nucleic acid having at least about 90% identity to the sequence 5'-GGCUGAGAACCAAAGAGUA-3' (SEQ ID NO:53) or a nucleic acid having at least about 90% identity to the sequence 5'-E1 passenger-3' (SEQ ID NO:37).
[0018] In some embodiments, the invention provides a method for treating a neurodegenerative synucleinopathic disease in a mammal comprising administering to the mammal an RNAi comprising a first strand comprising a first nucleic acid having at least about 90% identity to the sequence 5'-UGCUCUUUGGUCUUCUCAGCC-3' (SEQ ID NO:24) and a second strand comprising a second nucleic acid having at least about 90% identity to the sequence 5'-GGCUGAGAACCAAAGAGUA-3' (SEQ ID NO:53), or a first strand comprising a first nucleic acid having at least about 90% identity to the sequence 5'-UGGGCACAUUGGAACUGAGCA-3' (SEQ ID NO:8) and a second strand comprising a second nucleic acid having at least about 90% identity to the sequence 5'-UGCUCAGUCAAUGUGCCUA-3' (SEQ ID NO:37).
[0019] In some aspects, the present invention provides a method for inhibiting expression of alpha-synuclein in a mammal having a neurodegenerative disease, comprising administering to the mammal an RNAi comprising a first strand comprising a first nucleic acid having at least about 90% identity to the sequence 5'-UGCUCUUUGGUCUUCUCAGCC-3' (SEQ ID NO:24) or a first strand comprising a nucleic acid having at least about 90% identity to the sequence 5'-UGGGCACAUUGGAACUGAGCA-3' (SEQ ID NO:8), and a second strand comprising a second nucleic acid. In some embodiments, the second nucleic acid comprises a nucleic acid having at least about 90% identity to the sequence 5'-GGCUGAGAACCAAAGAGUA-3' (SEQ ID NO:53) or a nucleic acid having at least about 90% identity to the sequence 5'-UGCUCAGUCAAUGUGCCUA-3' (SEQ ID NO:37).
[0020] In some embodiments, the invention provides a method for inhibiting expression of alpha-synuclein in a mammal having a neurodegenerative disease, comprising administering to the mammal a first strand comprising a first nucleic acid having at least about 90% identity to the sequence 5'-UGCUCUUUGGUCUUCUCAGCC-3' (SEQ ID NO: 24) and a second strand comprising a second nucleic acid having at least about 90% identity to the sequence 5'-GGCUGAGAACCAAAGAGUA-3' (SEQ ID NO: 53), or a first strand comprising a first nucleic acid having at least about 90% identity to the sequence 5'-UGGGCACAUUGGAACUGAGCA-3' (SEQ ID NO: 8) and a second strand comprising a second nucleic acid having at least about 90% identity to the sequence 5'-UGCUCAGUCAAUGUGCCUA-3' (SEQ ID NO: 37). (c) administering to the subject a second strand comprising a second nucleic acid having at least about 90% identity to the target nucleic acid sequence.
[0021] In some embodiments of the above method, the first strand comprises a nucleic acid sequence having a sequence of SEQ ID NO:24 or a nucleic acid having a sequence of SEQ ID NO:8. In some embodiments, the second strand comprises a nucleic acid sequence having a sequence of SEQ ID NO:53 or a nucleic acid having a sequence of SEQ ID NO:37. In some embodiments, the first strand and the second strand are linked by an RNA linker capable of forming a loop structure. In some embodiments, the RNA linker comprises 4 to 50 nucleotides. In some embodiments, the loop structure comprises 4 to 20 nucleotides. In some embodiments, the RNAi is linked in a 5' to 3' direction to the second strand, the RNA linker. In some embodiments, the RNAi comprises, from 5' to 3', a first strand, an RNA linker, and a second strand. In some embodiments, the RNAi comprises a nucleic acid sequence of SEQ ID NO:61 or SEQ ID NO:63. In some embodiments, the RNAi comprises a nucleotide sequence that is about 90% identical to the nucleotide sequence of SEQ ID NO:61 or SEQ ID NO:63. In some embodiments, the RNAi is a small inhibitory RNA (siRNA), a microRNA (miRNA), or a small hairpin RNA (shRNA).
[0022] In some embodiments of the above method, RNAi targets RNA that codes for a polypeptide associated with neurodegenerative synucleinopathies.In some embodiments, the polypeptide is alpha-synuclein (SNCA).In some embodiments, the alpha-synuclein is human alpha-synuclein.In some embodiments, the neurodegenerative synucleinopathies are Parkinson's disease (PD), multiple system atrophy (MSA) or dementia with Lewy bodies (DLB).
[0023] In some embodiments of the above method, the present invention provides an expression construct comprising a nucleic acid encoding an RNAi as described herein. In some embodiments, the nucleic acid encoding the RNAi comprises a miRNA scaffold. In some embodiments, the nucleic acid encoding the RNAi is operably linked to a promoter. In some embodiments, the promoter is selected from the following: cytomegalovirus (CMV) immediate early promoter, RSV LTR, MoMLV LTR, phosphoglycerate kinase-1 (PGK) promoter, simian virus 40 (SV40) promoter, CK6 promoter, transthyretin promoter (TTR), TK promoter, tetracycline responsive promoter (TRE), HBV promoter, hAAT promoter, LSP promoter, chimeric liver specific promoter (LSP), E2F promoter, telomerase (hTERT) promoter; cytomegalovirus enhancer / chicken beta-actin / rabbit beta-globin promoter (CAG) promoter, elongation factor 1-alpha promoter (EF1-alpha) promoter, human beta-glucuronidase promoter, chicken beta-actin (CBA) promoter, retroviral Rous sarcoma virus (RSV) LTR promoter, dihydrofolate reductase promoter, and 13-actin promoter. In some embodiments, the expression construct further comprises an intron. In some embodiments, the intron is a CBA intron or a hEF1 alpha intron. In some embodiments, the intron is a chimeric intron. In some embodiments, the expression vector is a self-complementary vector and the intron is a delta chimeric intron. In some embodiments, the expression construct further comprises a polyadenylation signal. In some embodiments, the polyadenylation signal is a bovine growth hormone polyadenylation signal, an SV40 polyadenylation signal, or an HSV TK polyadenylation signal.
[0024] In some embodiments of the above method, the present invention provides a vector comprising any of the expression constructs described herein. In some embodiments, the vector is a recombinant adeno-associated virus (rAAV) vector. In some embodiments, the expression construct is flanked by one or more AAV inverted terminal repeat (ITR) sequences. In some embodiments, the expression construct is flanked by two AAV ITRs. In some embodiments, the AAV ITR is AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAVrh8, AAVrh8R, AAV9, AAV10, AAVrh10, AAV11, AAV12, AAV2R471A, AAV DJ, caprine AAV, bovine AAV, or mouse AAV serotype ITR. In some embodiments, the AAV ITR is AAV2 ITR. In some embodiments, the vector further comprises a stuffer nucleic acid. In some embodiments, the stuffer nucleic acid is located upstream or downstream of the nucleic acid that codes for RNAi.In some embodiments, the vector is a self-complementary rAAV vector.In some embodiments, the vector comprises a first nucleic acid sequence that codes for RNAi and a second nucleic acid sequence that codes for the complement of said RNAi, and the first nucleic acid sequence can form intrastrand base pairs with the second nucleic acid sequence over most or all of its length.In some embodiments, the first nucleic acid sequence and the second nucleic acid sequence are linked by the ITR of mutated AAV, and the ITR of mutated AAV comprises deletion of D region and comprises mutation of terminal resolution sequence.
[0025] In some embodiments of the above methods, the invention provides recombinant AAV particles comprising any of the rAAV vectors described herein. In some embodiments, the AAV viral particle comprises an AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAVrh8, AAVrh8R, AAV9, AAV10, AAVrhlO, AAV11, AAV12, AAV2R471A, AAV2 / 2-7m8, AAV DJ, AAV2 N587A, AAV2 E548A, AAV2 N708A, AAV V708K, AAV2-HBKO, AAVDJ8, AAVPHP.B, AAVPHP.eB, AAVBR1, AAVHSC15, AAVHSC17, caprine AAV, AAV1 / AAV2 chimera, bovine AAV, or murine AAV capsid rAAV2 / HBoV1 serotype capsid. In some embodiments, ITR and the capsid of rAAV viral particle are derived from the same AAV serotype. In some embodiments, ITR and the capsid of rAAV viral particle are derived from different AAV serotypes. In some embodiments, ITR is derived from AAV2, and the capsid of rAAV particle is derived from AAV1. In some embodiments, the rAAV particle is in the form of a composition. In some embodiments, the composition further comprises a pharma- ceutically acceptable carrier.
[0026] All references cited herein, including patent applications and publications, are hereby incorporated by reference in their entirety. [Brief description of the drawings]
[0027] [Figure 1] FIG. 1A shows the structure of the D1 shmiRNA (SEQ ID NO: 61), and FIG. 1B shows the structure of the E1 shmiRNA (SEQ ID NO: 63). [Diagram 2]1 is a graph showing RNAi-mediated reduction of human SNCA in vitro. Quantification of SNCA in whole cell extracts of HEK293T cells 72 hours after transfection with the indicated RNAi sequences in shmiRNA format and plasmids encoding human SNCA cDNA. SNCA levels were normalized to GAPDH loading control and normalized to control (non-targeting control RNAi) to calculate percent knockdown. [Diagram 3] 1 is a graph showing RNAi-mediated reduction of mouse SNCA in vitro. Quantification of SNCA in whole cell extracts of HEK293T cells 72 hours after transfection with a plasmid encoding the RNAi sequence in miRNA format and mouse SNCA cDNA. SNCA levels were normalized to GAPDH loading control and normalized to control (non-targeting control RNAi) to calculate percent knockdown. [Figure 4] 4A-D show RNAi-mediated reduction of mouse or human alpha-synuclein protein in vitro. Quantitative analysis of SNCA in whole cell extracts of HEK293T cells 72 hours after transfection with the indicated RNAi sequences in siRNA format and plasmids encoding human SNCA cDNA (FIG. 4A) or mouse SNCA cDNA (FIG. 4B). Protein levels of SNCA were normalized to beta tubulin and to control (non-targeting control RNAi) and percent knockdown was calculated as shown in the Western blotting images for human SNCA (FIG. 4C) and mouse SNCA (FIG. 4D). [Diagram 5]Figures 5A-B are graphs showing the toxicity of the indicated RNAi sequences in transfected LUHMES cells. LUHMES cells were transfected with the indicated RNAi sequences in miRNA format and then treated with rotenone to induce cytotoxicity. (Figure 5A) Cell viability was measured by Cell Titer Blue® assay 48 hours after rotenone treatment and demonstrated significant neuroprotection (38% and 40%, respectively) by both D1 and E1 RNAi sequences, but not for the control RNAi sequence. The % of mean neuroprotection is calculated as the % of change from control. (Figure 5B) Reactive oxygen species were measured as an additional readout of rotenone-induced toxicity. [Figure 6] Figure 1 shows the positive correlation of SNCA knockdown with neuroprotection. The percent neuroprotection (as cell viability) from Figure 5 was plotted against the level of knockdown from D1 or E1 in each experiment. Both RNAi sequences showed a significant positive correlation (Pearson's) of percent knockdown with the level of neuroprotection in rotenone-treated LUHMES cells. [Figure 7] Graph showing target mRNA knockdown by RNAi in miRNA format in vivo. Bars show mean + / - SEM. Circles represent individual animals. Significance was assessed by one-way ANOVA with multiple comparisons. [Figure 8] Figure 1 shows the reduction of SNCA mRNA across the midbrain of mice following injection of AAV-D1 vector. Mice were injected unilaterally with 1e10 GC of control or D1 virus. Tissues were collected and processed for in situ hybridization one month later. The SNCA antisense probe clearly shows targeted reduction at three different anatomical levels from rostral to caudal to the contralateral hemisphere. The control RNAi virus did not show any reduction of SNCA mRNA relative to the uninjected hemisphere. [Figure 9] FIG. 1 shows reduction of SNCA protein and mRNA in mice by SNc immunohistochemistry and in situ hybridization. [Figure 10]FIG. 1 shows SNc immunohistochemistry and in situ hybridization followed by reduction of SNCA protein and mRNA in mice by delivery of AAV.rh10-E1 vector. [Figure 11] FIG. 11 is a graph showing expression normalized to alpha-synuclein in individual biological replicates for each sample group; EV stands for "empty vector." DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0028] In some aspects, the present disclosure provides an RNAi for treating a neurodegenerative synucleinopathic disease. In some embodiments, the neurodegenerative synucleinopathic disease is Parkinson's disease or multiple system atrophy (MSA). In some embodiments, the RNAi targets alpha-synuclein. In some embodiments, the RNAi reduces expression of alpha-synuclein. In some embodiments, the RNAi comprises a first strand comprising a first nucleic acid comprising the sequence 5'-UGCUCUUUGGUCUUCUCAGCC-3' (SEQ ID NO: 24). In some embodiments, the RNAi comprises a first strand comprising a first nucleic acid comprising the sequence 5'-UGCUCUUUGGUCUUCUCAGCC-3' (SEQ ID NO: 24) and a second strand comprising a second nucleic acid comprising the sequence 5'-GGCUGAGAACCAAAGAGUA-3' (SEQ ID NO: 53). In some embodiments, the RNAi comprises a first strand comprising a first nucleic acid comprising the sequence 5'-UGGG The RNAi comprises a first strand comprising a first nucleic acid comprising the sequence 5'-UGGGCACAUUGGAACUGAGCA-3' (SEQ ID NO: 8). In some embodiments, the RNAi comprises a first strand comprising a first nucleic acid comprising the sequence 5'-UGGGCACAUUGGAACUGAGCA-3' (SEQ ID NO: 8) and a second strand comprising a second nucleic acid comprising the sequence 5'-UGCUCAGUCAAUGUGCCUA-3' (SEQ ID NO: 37). In some aspects, the present disclosure provides expression constructs, vectors (e.g., recombinant AAV vectors), cells, viral particles (e.g., AAV particles), and pharmaceutical compositions comprising the RNAi of the present disclosure. In further aspects, the present disclosure provides methods for treating neurodegenerative synucleinopathies, inhibiting expression of SNCA, and inhibiting accumulation of SNCA in mammalian cells, comprising administering to the mammal a pharmaceutical composition comprising the RNAi of the present disclosure. In yet a further aspect, the present disclosure provides the use of a pharmaceutical composition comprising the RNAi of the present disclosure for treating (e.g., alleviating symptoms of) neurodegenerative synucleinopathies, inhibiting the expression of SNCA, or inhibiting the accumulation of SNCA in mammalian cells having neurodegenerative synucleinopathies.In some embodiments, the synucleinopathies are Parkinson's disease, multiple system atrophy, or dementia with Lewy bodies.
[0029] I. General Techniques The techniques and procedures described or referred to herein are generally well recognized and commonly employed by those skilled in the art using conventional techniques, such as those described in, for example, Molecular Cloning: A Laboratory Manual (Sambrook et al., 4th ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 2012); Current Protocols in Molecular Biology (FMA Usubel et al., eds., 2003); Methods in Enzymology series (Academic Press, Inc.); PCR 2: A Practical Approach (MJ MacPherson, BD Hames and GR Taylor, eds., 1995); Antibodies, A Laboratory Manual (Harlow and Lane, eds., 1988); Culture of Animal Cells: A Manual of Basic Technique and Specialized Applications (RI Freshney, 6th ed., J. Wiley and Sons, 2010); Oligonucleotide Synthesis (MJ Gait, ed., 1984); Methods in Molecular Biology, Humana Press; Cell Biology: A Laboratory Notebook (ed. J. E. Elis, Academic Press, 1998); Introduction to Cell and Tissue Culture (ed. J. P. Mather and P. E. Oberts, Plenum Press, 1998); Cell and Tissue Culture: Laboratory Procedures (eds. A. Doyle, J. B. Griffiths, and D. G. Newell, J. Wiley and Sons, 1993-8); Handbook of Experimental Immunology (ed. D. M. Weir and CCBlackwell, 1996); Gene Transfer Vectors for Mammalian Cells (JM Miller and MP Calos, 1987); PCR: The Polymerase Chain Reaction, (Mullis et al., 1994); Current Protocols in Immunology (JE Coligan et al., 1991); Short Protocols in Molecular Biology (Ausubel et al., J. Wiley and Sons, 2002); Immunobiology (CA Janeway et al., 2004); Antibodies (P. Finch, 1997); Antibodies: A Practical Approach (D. Catty., IRL Press, 1988-19. 89);Monoclonal Antibodies: A Practical Approach (eds. P. Shepherd and C. Dean, Oxford University Press, 2000);Using Antibodies: A Laboratory Manual (eds. E. Harlow and D. Lane, Cold Spring Harbor Laboratory Press, 1999);The Antibodies (eds. M. Zanetti and JD Capra, Harwood Academic Publishers, 1995); and Cancer: Principles and Practice of Oncology (eds. VT DeVita et al., JBLippincott Company, 2011), which are widely used techniques.
[0030] II. Definition A "vector," as used herein, refers to a recombinant plasmid or virus containing a nucleic acid to be delivered to a host cell, either in vitro or in vivo.
[0031] The term "polynucleotide" or "nucleic acid" as used herein refers to a polymeric form of nucleotides of any length, either ribonucleotides or deoxyribonucleotides. Thus, the term includes, but is not limited to, single-stranded, double-stranded or multi-stranded DNA or RNA, genomic DNA, cDNA, DNA-RNA hybrids, or polymers containing purine and pyrimidine bases, or other natural, chemically or biochemically modified, non-natural, or derivatized nucleotide bases. The backbone of a polynucleotide may contain sugar and phosphate groups (as typically found in RNA or DNA), or may contain modified or substituted sugar or phosphate groups. Alternatively, the backbone of a polynucleotide may contain polymers of synthetic subunits such as phosphoramidates, and thus may be oligodeoxynucleoside phosphoramidates (P-NH2) or hybrid phosphoramidate-phosphodiester oligomers. In addition, double-stranded polynucleotides can be obtained from chemically synthesized single-stranded polynucleotide products by either synthesizing the complementary strand and annealing the strands under appropriate conditions, or by synthesizing the complementary strand de novo using DNA polymerase with an appropriate primer.
[0032] The terms "polypeptide" and "protein" are used interchangeably and refer to a polymer of amino acid residues, and are not limited to a minimum length. Such polymers of amino acid residues may contain natural or non-natural amino acid residues, including, but not limited to, peptides, oligopeptides, dimers, trimers, and multimers of amino acid residues. Both full-length proteins and their fragments are included in this definition. The term also encompasses post-expression modifications of the polypeptide, such as glycosylation, sialylation, acetylation, phosphorylation, and the like. Furthermore, for the purposes of this disclosure, "polypeptide" also refers to proteins that include modifications to the native sequence, such as deletions, additions, and substitutions (generally of a conservative nature), so long as the protein maintains the desired activity. These modifications may be deliberate, for example, via site-directed mutagenesis, or may be accidental, for example, via host mutations that produce proteins or errors by PCR amplification.
[0033] "Recombinant viral vector" refers to a recombinant polynucleotide vector that includes one or more heterologous sequences (i.e., nucleic acid sequences that are not of viral origin). In the case of recombinant AAV vectors, the recombinant nucleic acid is flanked by at least one, and in some embodiments two, inverted terminal repeats (ITRs).
[0034] A "recombinant AAV vector (rAAV vector)" refers to at least one, and rAAV refers to a polynucleotide vector that contains one or more heterologous sequences (i.e., nucleic acid sequences not derived from AAV) flanked by two AAV inverted terminal repeats (ITRs) in the rAAV vector. Such rAAV vectors can replicate and be packaged into infectious viral particles when present in a host cell infected with a suitable helper virus (or expressing suitable helper functions) and expressing the AAV rep and cap gene products (i.e., AAV Rep and Cap proteins). When the rAAV vector is incorporated into a larger polynucleotide (e.g., in a chromosome or in another vector, such as a plasmid used for cloning or transfection), the rAAV vector may also be referred to as a "pro-vector" that can be "rescued" by replication and encapsidation in the presence of AAV packaging functions and suitable helper functions. The rAAV vector may be in any of a number of forms, including, but not limited to, a plasmid, linear artificial chromosome, complexed with lipids, encapsulated in liposomes, and encapsidated in viral particles, particularly AAV particles. The rAAV vector can be packaged into the capsid of the AAV virus to generate a "recombinant adeno-associated viral particle (rAAV particle)."
[0035] "Heterologous" means derived from an entity having a genotype distinct from that of the remainder of the entity to which it is compared or introduced or incorporated. For example, a polynucleotide introduced into a different cell type by genetic engineering techniques is a heterologous polynucleotide (which can encode a heterologous polypeptide when expressed). Similarly, a cellular sequence (e.g., a gene or a portion thereof) incorporated into a viral vector is a heterologous nucleotide sequence with respect to that vector.
[0036] The term "transgene" refers to a polynucleotide that can be introduced into a cell and transcribed into RNA, and can optionally be translated and / or expressed under appropriate conditions.In an embodiment, the transgene confers a desired characteristic to the cell into which it is introduced, or otherwise produces a desired therapeutic or diagnostic result.In another embodiment, the transgene can be transcribed into a molecule that mediates RNA interference, such as miRNA, siRNA, or shRNA.
[0037] "Chicken β-actin (CBA) promoter" refers to a polynucleotide sequence derived from a chicken β-actin gene (e.g., chicken (Gallus gallus) beta actin, designated Entrez gene number 396526 in GenBank). "Chicken β-actin promoter" as used herein may refer to a promoter containing a cytomegalovirus (CMV) early enhancer element, the promoter and first exon and intron of the chicken β-actin gene, and the splice acceptor of the rabbit beta-globin gene, such as the sequence described in Miyazaki, J. et al. (1989) Gene 79(2):269-77. The term "CAG promoter" as used herein may be used synonymously. The term "CMV early enhancer / chicken beta actin (CAG) promoter" as used herein may be used synonymously.
[0038] The terms "genome particles (gp)", "genome equivalents", or "genome copies", when used in reference to viral titer, refer to the number of virions containing the DNA genome of a recombinant AAV, regardless of infectivity or functionality. The number of genome particles in a particular vector preparation can be measured by procedures such as those described in the Examples herein or, for example, in Clark et al. (1999) Hum. Gene Ther., 10:1031-1039; Veldwijk et al. (2002) Mol. Ther., 6:272-278.
[0039] The term "vector genome (vg)" as used herein refers to a vector, e.g. AAV vector genome may refer to one or more polynucleotides that comprise a set of polynucleotide sequences of a viral vector. A vector genome may be encapsidated in a viral particle. Depending on the particular viral vector, the vector genome may comprise single-stranded DNA, double-stranded DNA, or single-stranded RNA, or double-stranded RNA. A vector genome may include endogenous sequences associated with a particular viral vector and / or any heterologous sequences inserted into a particular viral vector via recombinant techniques. For example, a recombinant AAV vector genome may include at least one ITR sequence at the end of a promoter, a stuffer, a sequence of interest (e.g., RNAi), and a polyadenylation sequence. A complete vector genome may include a complete set of polynucleotide sequences of a vector. In some embodiments, the titer of the nucleic acid of the viral vector can be measured in vg / mL. Suitable methods for measuring the titer are known in the art (e.g., quantitative PCR).
[0040] As used herein, the term "inhibit" refers to the action of blocking, reducing, eliminating, or otherwise antagonizing the presence or activity of a particular target. Inhibition refers to partial or complete inhibition. For example, inhibiting the expression of a gene refers to any action that results in blocking, reducing, eliminating, or any other antagonism of gene expression, including reducing the abundance of mRNA (e.g., silencing mRNA transcription), degrading mRNA, inhibiting mRNA translation, etc. In some embodiments, inhibiting the expression of SNCA refers to blocking, reducing, eliminating, or any other antagonism of SNCA expression, including reducing the abundance of SNCA mRNA (e.g., silencing SNCA mRNA transcription), degrading SNCA mRNA, inhibiting SNCA mRNA translation, etc. As another example, inhibiting the accumulation of a protein in a cell refers to any action that results in blocking, reducing, eliminating, or any other antagonism of protein expression, including reducing the abundance of mRNA (e.g., silencing mRNA transcription), degrading mRNA, inhibiting mRNA translation, degrading protein, etc. In some embodiments, inhibiting accumulation of SNCA protein in a cell refers to blocking, reducing, eliminating, or otherwise antagonizing the expression of SNCA protein in a cell, including reducing the abundance of SNCA mRNA (e.g., silencing SNCA mRNA transcription), degrading SNCA mRNA, inhibiting SNCA mRNA translation, degrading SNCA protein, etc.
[0041] The terms "infectious unit (iu)," "infectious particle," or "replication unit," when used in reference to viral titer, refer to the number of infectious and replication-competent recombinant AAV vector particles as measured by the infectious center assay, also known as the replication center assay, e.g., as described in McLaughlin et al. (1988) J. Virol., 62:1963-1973.
[0042] The term "transducing unit (tu)", when used in reference to viral titer, refers to the number of infectious recombinant AAV vector particles that result in the production of a functional transgene product, as measured in the Examples herein, or in a functional assay such as those described, for example, in Xiao et al. (1997) Exp. Neurobiol., 144:113-124; or Fisher et al. (1996) J. Virol., 70:520-532 (LFU assay).
[0043] "Inverted terminal repeat" or "ITR" sequences are a term well understood in the art and refer to relatively short sequences found at the ends of viral genomes in inverted orientation.
[0044] "AAV inverted terminal repeat (ITR)" sequences, a term well understood in the art, are sequences of approximately 145 nucleotides present at both ends of a native single-stranded AAV genome. The outermost 125 nucleotides of the ITRs can be arranged in either of two alternative orientations, resulting in heterogeneity between different AAV genomes and between the two ends of a single AAV genome. The outermost 125 nucleotides may also contain several shorter regions of self-complementarity (designated the A, A', B, B', C, C' and D regions), which allow intrastrand base pairing to occur within this portion of the ITR.
[0045] "Terminal resolution sequence" or "trs" is a sequence in the D region of the AAV ITR that is cleaved by the AAV rep protein during viral DNA replication. The mutated terminal resolution sequence is resistant to cleavage by the AAV rep protein.
[0046] "AAV helper function" refers to the function that allows AAV to replicate and package by host cell.AAV helper function can be provided in any of many forms, including but not limited to helper virus or helper virus gene that helps AAV replication and packaging.Other AAV helper functions are known in the field, such as genotoxic agents.
[0047] A "helper virus" for AAV refers to a virus that allows AAV (which is a defective parvovirus) to replicate and be packaged by a host cell. Helper viruses provide "helper functions" that allow AAV to replicate. Many such helper viruses have been identified, including adenoviruses, herpesviruses, and poxviruses, such as vaccinia and baculovirus. Adenoviruses encompass many different subgroups, with adenovirus type 5 (Ad5) of subgroup C being the most commonly used. Numerous adenoviruses of human, non-human mammalian, and avian origin are known and available from depositories such as ATCC. Herpes family viruses that are also available from depositories such as ATCC include, for example, herpes simplex virus (HSV), Epstein-Barr virus (EBV), cytomegalovirus (CMV), and pseudorabies virus (PRV). Examples of adenoviral helper functions for AAV replication include E1A, E1B, E2A, VA and E4orf6 functions. Baculoviruses available from depositories include Autographa californica nuclear polyhedrosis virus.
[0048] The rAAV preparations are prepared with a ratio of infectious AAV particles to infectious helper virus particles of at least about 10. 2 :1; at least about 10 4 :1, at least about 10 6 :1; or at least about 10 8A preparation is said to be "substantially free" of helper virus if its concentration is 0.1 or higher. In some embodiments, the preparation also does not contain a corresponding amount of helper virus protein (i.e., protein that would be expected to be present as a result of such levels of helper virus if the above-mentioned helper virus particle impurities were present in a disrupted form). Contaminating viral and / or cellular proteins can generally be observed as the presence of Coomassie stained bands in SDS gels (e.g., the appearance of bands other than those corresponding to the AAV capsid proteins VP1, VP2 and VP3).
[0049] "Percent (%) sequence identity" to a reference polypeptide or nucleic acid sequence is defined as the percentage of amino acid residues or nucleotides in a candidate sequence that are identical to the amino acid residues or nucleotides in the reference polypeptide or nucleic acid sequence after aligning the sequences to achieve the maximum percent sequence identity and introducing gaps, if necessary, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid or nucleic acid sequence identity can be performed in a variety of ways within the skill of the art, for example, using publicly available computer software programs, such as those described in Current Protocols in Molecular Biology (Ausubel et al., eds., 1987), Supplement 30, section 7.7.18, Table 7.7.1. Alignment can be achieved using the software described in the above, such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR). A preferred alignment program is ALIGN Plus (Scientific and Educational Software, Pennsylvania). Those skilled in the art can determine the appropriate parameters for measuring alignment, such as any algorithms required to achieve maximum alignment over the entire length of the sequences being compared. For the purposes described herein, the % amino acid sequence identity of a given amino acid sequence A to, with, or against a given amino acid sequence B (alternatively, it can be expressed as a given amino acid sequence A having or containing a certain % amino acid sequence identity to, with, or against a given amino acid sequence B) is calculated as follows: 100 x fraction X / Y, where X is the number of amino acid residues scored as identical matches by a sequence alignment program in the alignment of A and B in that program, and Y is the total number of amino acid residues in B. It is understood that if the length of amino acid sequence A is not equal to the length of amino acid sequence B, the % amino acid sequence identity of A to B is not expected to be equal to the % amino acid sequence identity of B to A. For the purposes described herein, the % nucleic acid sequence identity of a given nucleic acid sequence C to, with, or to a given nucleic acid sequence D (alternatively, it can be expressed as a given nucleic acid sequence C having or containing a certain % nucleic acid sequence identity to, with, or to a given nucleic acid sequence D) is calculated as follows: 100 x fraction W / Z, where W is the number of nucleotides scored as identical matches by a sequence alignment program in the alignment of C and D in that program, and Z is the total number of nucleotides in D. It is understood that if the length of a nucleic acid sequence C is not equal to the length of nucleic acid sequence D, the % nucleic acid sequence identity of C to D is not expected to be equal to the % nucleic acid sequence identity of D to C.
[0050] An "isolated" molecule (eg, a nucleic acid or protein) or cell means that it has been identified and separated and / or recovered from a component of its natural environment.
[0051] An "effective amount" is an amount sufficient to effect a beneficial or desired result, such as a clinical result (e.g., alleviation of symptoms, achievement of a clinical endpoint, etc.). An effective amount can be administered in one or more administrations. In terms of a disease state, an effective amount is an amount sufficient to alleviate, stabilize, or delay the onset of a disease.
[0052] An "individual" or "subject" is a mammal. Mammals include, but are not limited to, domestic animals (e.g., cows, sheep, cats, dogs, and horses), primates (e.g., humans and non-human primates such as monkeys), rabbits, and rodents (e.g., mice and rats). In certain embodiments, an individual or subject is a human.
[0053] "Treatment" as used herein is an approach to obtain beneficial or desired clinical results. For the purposes of this disclosure, beneficial or desired clinical results include, but are not limited to, alleviation of symptoms, whether detectable or undetectable, reduction in the extent of disease, a stabilized (e.g., not worsening) state of disease, prevention of disease spread (e.g., metastasis), delay or slowing of disease progression, alleviation or palliative relief of symptoms, and remission (whether partial or complete). "Treatment" can also mean prolonging survival compared to expected survival in the absence of treatment.
[0054] The term "prophylactic treatment" as used herein refers to treatment where an individual is known or suspected to have or be at risk of having a disorder, but exhibits no or minimal symptoms of the disorder. An individual receiving prophylactic treatment is treated prior to the onset of symptoms.
[0055] As used herein, the term "neurodegenerative synucleinopathy" refers to neurodegenerative disorders characterized by fibrillar aggregation of alpha-synuclein protein in the cytoplasm of selected populations of neurons and glia in both central and peripheral nervous systems.Examples include, but are not limited to, Parkinson's disease (PD), multiple system atrophy (MSA-P and MSA-C), dementia with Lewy bodies (DLB), pure autonomic dysfunction (PAF), Lewy body variant of Alzheimer's disease (LBVAD), Lewy body dysphagia, and incidental Lewy body disease.
[0056] As used herein, "RNAi" refers to any RNA molecule that induces RNA interference in cells.Examples of RNAi include but are not limited to small inhibitory RNA (siRNA), microRNA (miRNA) or small hairpin RNA (shRNA).
[0057] "miRNA scaffold" refers to a polynucleotide that contains (i) a double-stranded sequence that targets a gene of interest for knockdown by RNAi and (ii) an additional sequence that forms a stem-loop structure similar to that of endogenous miRNA. The sequence that targets a gene of interest for RNAi (e.g., a short, about 20nt sequence) is ligated to a sequence that creates a miRNA-like stem-loop and a sequence that base pairs with the sequence of interest to form a double strand when the polynucleotide is assembled into a miRNA-like secondary structure. As described herein, this double strand is incompletely hybridized, e.g., the double strand contains one or more unpaired or mispaired bases. Upon cleavage of this polynucleotide by Dicer, the double strand that contains the sequence that targets the gene of interest is unwound and incorporated into the RISC complex. miRNA scaffold refers to the miRNA itself or to the DNA polynucleotide that encodes the miRNA. An example of a miRNA scaffold is the miR-155 sequence (Lagos-Quintana, M et al. (2002) Curr. Biol. 12:735-9). Commercially available kits for cloning sequences into miRNA scaffolds are known in the art (e.g., Invitrogen™ BLOCK-iT™ Pol II miR RNAi Expression Vector Kit from Life Technologies, Thermo Fisher Scientific; Waltham, Mass.).
[0058] As used herein, "bulge" refers to a region of nucleic acid that is non-complementary to the opposite nucleic acid in double-stranded nucleic acid. For example, a bulge refers to a nucleic acid sequence that is non-complementary to the opposite nucleic acid in double-stranded nucleic acid, where the bulge is adjacent to the region of nucleic acid that is complementary to the opposite nucleic acid in double-stranded nucleic acid. In some cases, the bulge is either 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more than 10 bases long. In some cases, the bulge is the result of mismatching (e.g., the opposite strand contains a base that is non-complementary) or the bulge is the result of non-matching (e.g., the opposite strand contains a nucleic acid that is complementary to the nucleic acid adjacent to the bulge, but the opposite strand does not contain the nucleic acid opposite the bulge).
[0059] As used herein, the term "sense" nucleic acid is a nucleic acid that comprises a sequence that codes for all or part of a transgene. In some instances, an mRNA for a transgene is a sense nucleic acid.
[0060] As used herein, an "antisense" nucleic acid is a sequence of nucleic acid that is complementary to a "sense" nucleic acid. For example, an antisense nucleic acid is complementary to an mRNA encoding a transgene.
[0061] As used herein, a "guide region" of an RNAi is typically the strand of an RNAi that binds to a target mRNA based on complementarity. The complementary region is the entire length of the guide region. Or a part thereof. Typically, the complementary region includes at least the seed region. In many cases, the antisense region of the RNAi is the guide region.
[0062] As used herein, the "passenger region" or "non-guide region" of an RNAi, which are used interchangeably herein, is the region of the RNAi that is complementary to the guide region.In many cases, the sense region of an RNAi is the passenger region.
[0063] As used herein, the "seed region" of an RNAi (e.g., miRNA) is a region of the microRNA that is about 1-8 nucleotides in length. In some instances, the seed region and 3'-UTR of its target mRNA are key determinants in RNAi recognition.
[0064] As used herein, "off-target gene silencing" refers to the pairing of the seed region of RNAi with sequences in the 3'-UTR of unintended mRNAs, leading to the repression of translation and destabilization of those transcripts (e.g., reducing expression of the unintended mRNAs).
[0065] Reference herein to a value or parameter "with respect to" encompasses (describes) embodiments directed to that value or parameter per se. For example, a reference "with respect to X" encompasses a description of "X."
[0066] As used herein, the singular articles "a," "an," and "the" include plural referents unless otherwise specified.
[0067] It is understood that aspects and embodiments of the disclosure described herein encompass "comprising," "consisting," and / or "consisting essentially of" aspects and embodiments.
[0068] III. RNAi In some aspects, the present disclosure provides improved RNAi. In some embodiments, the RNAi is a small inhibitory RNA (siRNA), a microRNA (miRNA), or a small hairpin RNA (shRNA). Small inhibitory or interfering RNA (siRNA) is known in the art as a double-stranded RNA molecule of approximately 19-25 (e.g., 19-23) base pairs in length that induces RNAi in cells. In some embodiments, siRNA sequences can also be inserted into an artificial miRNA scaffold ("shmiRNA"). Small hairpin RNA (shRNA) is known in the art as an RNA molecule that includes approximately 19-25 (e.g., 19-23) base pairs in length of double-stranded RNA linked by a short loop (e.g., about 4-11 nucleotides) that induces RNAi in cells.
[0069] MicroRNA (miRNA) is known in the art as an RNA molecule that induces RNAi in cells and contains a short (e.g., 19-25 base pairs) sequence of double-stranded RNA connected by a loop, and contains one or more additional sequences of double-stranded RNA that contain one or more bulges (e.g., mismatched or unpaired base pairs). As used herein, the term "miRNA" encompasses endogenous miRNA and exogenous or heterologous miRNA. In some embodiments, "miRNA" refers to pri-miRNA or pre-miRNA. During miRNA processing, a pri-miRNA transcript is generated. The pri-miRNA is processed by Drosha-DGCR8 and contains the 5' flanking region, guide strand, loop region, non-guide strand, and 3' flanking region; or the 5' flanking region, non-guide strand, loop region, guide strand, and 3' flanking region. The miRNA is then transported to the cytoplasm and processed by Dicer to generate a siRNA having a guide strand and a non-guide (or passenger) strand. The guide strand is then used by the RISC complex to catalyze gene silencing, for example, by recognizing a target RNA sequence complementary to the guide strand. Further description of miRNAs can be found, for example, in WO2008 / 150897. Recognition of a target sequence by a miRNA is determined primarily by pairing of the target with the seed sequence of the miRNA, for example, nucleotides 1-8 (5' to 3') of the guide strand (see, for example, Boudreau, RL et al. (2013) Nucleic Acids Res. 41:e9).
[0070] In the pri / pre-miRNA structure, the guide strand:non-guide strand boundary in the duplex is formed, in part, through complementary base pairing (e.g., Watson-Crick flag base pairing). However, in some embodiments, this complementary base pairing does not extend across the entire duplex. In some embodiments, a bulge in the boundary is present at one or more nucleotide positions. As used herein, the term "bulge" refers to a region of a nucleic acid that is non-complementary to the nucleic acid opposite it in the duplex. In some embodiments, a bulge is formed when a region of complementary nucleic acid binds to each other while a region of the central non-complementary region does not bind. In some embodiments, a bulge is formed when the two strands of nucleic acid located between the two complementary regions have different lengths. As described below, the bulge comprises one or more nucleotides. In some embodiments, the miRNA comprises an internal bulge created by deleting two bases (bases 9-10, counting from the start of the passenger strand) from the passenger strand of the miRNA.
[0071] In another aspect, the RNAi described in this disclosure is inhibitory to alpha-synuclein (SNCA). In some embodiments, the SNCA is mouse SNCA. In some embodiments, the SNCA is human SNCA. In some embodiments, the RNAi targets the RNA encoding SNCA. In some embodiments, the RNAi inhibits the expression of SNCA in a subject. In some embodiments, the RNAi inhibits the accumulation of SNCA in a subject. In some embodiments, the subject is a mammal. In some embodiments, the mammal is a human.
[0072] The safety of RNAi-based therapeutics is hampered by the ability of small inhibitory RNAs (siRNAs) to bind to unintended mRNAs and reduce their expression, an effect known as off-target gene silencing. Off-targeting occurs primarily when the seed region (nucleotides 2-8 of a small RNA) pairs with sequences in the 3'-UTR of unintended mRNAs, leading to translational repression and destabilization of their transcripts. RNAi with reduced off-targeting can be designed by substituting bases in the guide and non-guide sequences; for example, by creating CpG motifs. Substitutions that may result in significantly lower off-target scores can be evaluated using the SiSPOTR algorithm, a specificity-focused siRNA design algorithm that identifies candidate sequences with minimal off-targeting potential and potent silencing capacity (Boudreau et al., Nucleic Acids Res. January 2013; 41(1)e9). Reduced SiSPOTR scores predict sequences with fewer potential human off-targets compared to the parent RNAi molecule. In some embodiments of the present disclosure, RNAi is improved to reduce off-target gene silencing.In some embodiments, RNAi comprises one or more CpG motifs.In some embodiments, RNAi comprises one or more CpG motifs in seed region.
[0073] In some embodiments, the first strand and the second strand are linked by RNA (e.g., RNA linker) that can form a loop structure.As generally known in the art, an RNA loop structure (e.g., stem-loop or hairpin) is formed when an RNA molecule comprises two sequences of RNA that base-pair with each other, separated by a sequence of RNA that does not base-pair with each other.For example, a loop structure can be formed in an RNA molecule ABC when sequences A and C are complementary or partially complementary so that they base-pair with each other, but the bases in sequence B do not base-pair together.In some embodiments, the loop sequence is 5'-GTTTTGGCCACTGACTGAC-3' (SEQ ID NO:59) in DNA form or 5'-GUUUUGGCCACUGACUGAC-3' (SEQ ID NO:60) in RNA form.
[0074] In some embodiments, the RNA capable of forming a loop structure comprises 4 to 50 nucleotides. In certain embodiments, the RNA capable of forming a loop structure comprises 13 nucleotides. In some embodiments, the number of nucleotides in the RNA capable of forming a loop is 4 to 50 nucleotides or any integer therebetween. In some embodiments, 0 to 50% of the loop is complementary to another portion of the loop. As used herein, the term "loop structure" is a sequence that connects two complementary strands of a nucleic acid. In some embodiments, 1 to 3 nucleotides of the loop structure are adjacent to the complementary strand of the nucleic acid and are complementary to 1 to 3 nucleotides of the distal portion of the loop structure. For example, the three nucleotides at the 5' end of the loop structure are complementary to the three nucleotides at the 3' end of the loop structure.
[0075] In some embodiments, the nucleic acid encoding the RNAi of the present disclosure comprises a heterologous miRNA scaffold. In some embodiments, the use of a heterologous miRNA scaffold regulates miRNA expression; for example, it is used to increase miRNA expression or decrease miRNA expression. Any miRNA scaffold known in the art can be used. In some embodiments, the miRNA scaffold is derived from the miR-155 scaffold (see, for example, Lagos-Quintana, M. et al. (2002) Curr. Biol. 12:735-9 and the Invitrogen™ BLOCK-iT™ Pol II miR RNAi Expression Vector Kit from Life Technologies, Thermo Fisher Scientific; Waltham, MA).
[0076] In some embodiments, the RNAi is selected from Table 1.
[0077] In some embodiments, the first strand comprises a nucleic acid sequence having a percentage identity of about 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% or more to any guide sequence. In some embodiments, the first strand comprises a nucleic acid sequence having a percentage identity of about 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% or more to any guide sequence, but maintaining a CpG motif. In some embodiments, the second strand comprises a nucleic acid sequence having a percentage identity of about 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% or more to the corresponding passenger sequence. In some embodiments, the second strand comprises a nucleic acid sequence having a percentage identity to the corresponding passenger sequence greater than about any of 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%, but maintains a CpG motif.
[0078] [Table 1]
[0079] IV. Neurodegenerative synucleinopathies Neurodegenerative synucleinopathies involve the transcription factor alpha synuclein in neurons, nerve fibers or glial cells. Syncytial cell death syndrome (SCS) is a neurodegenerative disease characterized by elevated levels of the neurotransmitter synuclein (SNCA) protein. The main types of neurodegenerative synucleinopathies include dementia with Lewy bodies (DLB), Parkinson's disease, and multiple system atrophy (MSA).
[0080] Examples of neurodegenerative synucleinopathies include, but are not limited to, Parkinson's disease (PD), multiple system atrophy (MSA-P and MSA-C), dementia with Lewy bodies (DLB), pure autonomic dysregulation (PAF), Lewy body variant of Alzheimer's disease (LBVAD), Lewy body dysphagia, and incidental Lewy body disease.
[0081] Multiple lines of evidence suggest that elevated alpha-synuclein levels lead to neurotoxicity On the other hand, reduction has been demonstrated to be neuroprotective (Dauer, 2002; Drolet, 2004; Alvarez-Fischer, 2008; Klivenyi, 2005; Mittal, 2017; Javed, 2015; Cole, 2017; Ubhi, 2010; Lim, 2011). In the present disclosure, RNAi against SNCA is provided.
[0082] V. Methods for Treating Neurodegenerative Synucleinopathies In some embodiments, the present disclosure provides methods and compositions for treating a neurodegenerative synucleinopathic disease in a mammal, comprising administering to the mammal a pharmaceutical composition of the present disclosure (e.g., a pharmaceutical composition comprising a viral particle of the present disclosure). In some embodiments, the present disclosure provides methods and compositions for inhibiting expression of SNCA in a mammal having a neurodegenerative synucleinopathic disease, comprising administering to the mammal a pharmaceutical composition of the present disclosure (e.g., a pharmaceutical composition comprising a viral particle of the present disclosure). In some embodiments, the present disclosure provides methods and compositions for inhibiting accumulation of SNCA in cells of a mammal having a neurodegenerative synucleinopathic disease, comprising administering to the mammal a pharmaceutical composition of the present disclosure (e.g., a pharmaceutical composition comprising a viral particle of the present disclosure).
[0083] In some aspects, the present disclosure provides methods and compositions for alleviating symptoms of neurodegenerative synucleinopathies, comprising administering to the nervous system of a mammal an effective amount of recombinant viral particles comprising the vector encoding the RNAi of the present disclosure.In some embodiments, symptoms of neurodegenerative synucleinopathies include, but are not limited to, Parkinson's syndrome, cognitive impairment, sleep disorder, visual hallucinations, speech disorder, constipation, pyramidal or cerebellar signs, anosmia, autonomic neuropathy, such as orthostatic hypotension, hypohidrosis, erectile dysfunction, urinary retention or incontinence, and pupillary dysfunction.
[0084] In some embodiments, the present disclosure provides a method for preventing or delaying the progression of neurodegenerative synucleinopathies.Synucleinopathies-like PD are typically clinically diagnosed by the presence of tremor, bradykinesia, rigidity, and postural sway.Distinguishing from PD is typically performed by checking additional symptoms such as orthostatic hypotension, pyramidal signs, cognitive changes, or hallucinations.In addition, some synucleinopathies can be diagnosed by brain imaging, for example, by looking for abnormalities in brain regions such as the pons, cerebellum, and putamen in MSA.Some synucleinopathies can be directly identified by genotyping for common mutations that are not necessarily limited to the SNCA gene. Slowing or prevention of disease progression is defined by improvement in any of the following symptoms: motor function (bradykinesia, dystonia, postural sway, hunched posture, tremor, myoclonus, etc.), cognition, sleep disturbance, visual hallucinations, speech, constipation, pyramidal signs, anosmia, autonomic dysfunction such as orthostatic hypotension, hypohidrosis, erectile dysfunction, urinary retention or incontinence, and pupillary dysfunction.
[0085] In some aspects of the present disclosure, the methods and compositions are used to treat humans with neurodegenerative synucleinopathies. In some aspects, the present disclosure provides improved RNAi for targeting SNCA mRNA in mammals with neurodegenerative synucleinopathies. In some embodiments, the RNAi comprises a first strand comprising a first nucleic acid comprising the sequence 5'-UGCUCUUUGGUCUUCUCAGCC-3' (SEQ ID NO: 24) and a second strand comprising a second nucleic acid comprising the sequence 5'-GGCUGAGAACCAAAGAGUA-3' (SEQ ID NO: 53), the first strand and the second strand forming a duplex, and the A residue at residue 19 of SEQ ID NO: 53 of the second strand does not base pair with a residue of the first strand. In some embodiments, the miRNA comprises an internal bulge created by deleting two bases (bases 9-10, counting from the start of the passenger strand) from the passenger strand of the miRNA. In some embodiments, the first strand and the second strand are linked by a loop sequence. In some embodiments, the loop sequence is 5'-GUUUUGGCCACUGACUGAC-3' (SEQ ID NO: 60).
[0086] In some embodiments, the RNAi comprises a first strand comprising a first nucleic acid comprising the sequence 5'-UGGGCACAUUGGAACUGAGCA-3' (SEQ ID NO: 8) and a second strand comprising a second nucleic acid comprising the sequence 5'-UGCUCAGUCAAUGUGCCUA-3' (SEQ ID NO: 37), wherein the first strand and the second strand form a duplex, and A residue 19 of SEQ ID NO: 37 of the second strand does not base pair with a residue of the first strand. In some embodiments, the miRNA comprises an internal bulge created by deleting two bases (bases 9-10, counting from the start of the passenger strand) from the passenger strand of the miRNA. In some embodiments, the first strand and the second strand are linked by a loop sequence. In some embodiments, the loop sequence is 5'-GUUUUGGCCACUGACUGAC-3' (SEQ ID NO: 60).
[0087] In some embodiments, the RNAi comprises a first strand comprising a first nucleic acid comprising the sequence 5'-UGCGCUUUGGUCUUCUCAGCC-3' (SEQ ID NO: 14) and a second strand comprising a second nucleic acid comprising the sequence 5'-GGCUGAGAACCAAAGCGUA-3' (SEQ ID NO: 43), wherein the first strand and the second strand form a duplex and the A residue at residue 19 of SEQ ID NO: 43 of the second strand does not base pair with a residue of the first strand. In some embodiments, the miRNA comprises an internal bulge created by deleting two bases (bases 9-10, counting from the start of the passenger strand) from the passenger strand of the miRNA. In some embodiments, the first strand and the second strand are linked by a loop sequence. In some embodiments, the loop sequence is 5'-GUUUUGGCCACUGACUGAC-3' (SEQ ID NO: 60).
[0088] In some embodiments, the RNAi comprises a first strand comprising a first nucleic acid comprising the sequence 5'-UGGGCGCAUUGGAACUGAGCA-3' (SEQ ID NO: 7) and a second strand comprising a second nucleic acid comprising the sequence 5'-UGCUCAGUCAAUGCGCCUA-3' (SEQ ID NO: 36), wherein the first strand and the second strand form a duplex, and the A residue at residue 19 of SEQ ID NO: 36 of the second strand does not base pair with a residue of the first strand. In some embodiments, the miRNA comprises an internal bulge created by deleting two bases (bases 9-10, counting from the start of the passenger strand) from the passenger strand of the miRNA. In some embodiments, the first strand and the second strand are linked by a loop sequence. In some embodiments, the loop sequence is 5'-GUUUUGGCCACUGACUGAC-3' (SEQ ID NO: 60).
[0089] In some embodiments, the RNAi comprises a first strand comprising a first nucleic acid comprising the sequence 5'-uUCCAACAUUUGUCACUUGCU-3' (SEQ ID NO: 5) and a second strand comprising a first nucleic acid comprising the sequence 5'-AG and a second strand comprising a second nucleic acid comprising CAAGUGAAAUGUUCGAA-3' (SEQ ID NO: 34), wherein the first strand and the second strand form a duplex, and the A residue at residue 18 or residue 19 of SEQ ID NO: 34 of the second strand does not base pair with a residue of the first strand. In some embodiments, the miRNA comprises an internal bulge created by deleting two bases (bases 9-10, counting from the start of the passenger strand) from the passenger strand of the miRNA. In some embodiments, the first strand and the second strand are linked by a loop sequence. In some embodiments, the loop sequence is 5'-GUUUUGGCCACUGACUGAC-3' (SEQ ID NO: 60).
[0090] In some embodiments of the present disclosure, RNAi is improved to reduce off-target gene silencing.In some embodiments, RNAi comprises one or more CpG motifs.In some embodiments, RNAi comprises one or more CpG motifs in seed region.
[0091] In some embodiments, the present disclosure provides a method for treating a neurodegenerative synucleinopathic disease in a mammal comprising administering to the mammal an RNAi comprising a first strand comprising a first nucleic acid comprising the sequence 5'-UGCUCUUUGGUCUUCUCAGCC-3' (SEQ ID NO: 24) and a second strand comprising a second nucleic acid comprising the sequence 5'-GGCUGAGAACCAAAGAGUA-3' (SEQ ID NO: 53), wherein the first strand and the second strand form a duplex. In some embodiments, the miRNA comprises an internal bulge created by deleting two bases (bases 9-10, counting from the start of the passenger strand) from the passenger strand of the miRNA. In some embodiments, the present disclosure provides a method for inhibiting expression of SNCA in a mammal having a neurodegenerative synucleinopathic disease comprising administering to the mammal an RNAi comprising a first strand comprising a first nucleic acid comprising the sequence 5'-UGCUCUUUGGUCUUCUCAGCC-3' (SEQ ID NO:24) and a second strand comprising a second nucleic acid comprising the sequence 5'-GGCUGAGAACCAAAGAGUA-3' (SEQ ID NO:53), wherein the first strand and the second strand form a duplex. In some embodiments, the present disclosure provides a method for inhibiting accumulation of SNCA in cells of a mammal having a neurodegenerative synucleinopathic disease comprising administering to the mammal an RNAi comprising a first strand comprising a first nucleic acid comprising the sequence 5'-UGCUCUUUGGUCUUCUCAGCC-3' (SEQ ID NO: 24) and a second strand comprising a second nucleic acid comprising the sequence 5'-GGCUGAGAACCAAAGAGUA-3' (SEQ ID NO: 53), wherein the first strand and the second strand form a duplex. In some embodiments, the miRNA comprises an internal bulge created by deleting two bases (bases 9-10, counting from the start of the passenger strand) from the passenger strand of the miRNA. In some embodiments, the first strand comprises a nucleic acid sequence having a percentage identity greater than about any of 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% to SEQ ID NO: 24.In some embodiments, the second strand comprises a nucleic acid sequence having a percentage identity greater than about any of 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% to SEQ ID NO: 24, but maintains a CpG motif. In some embodiments, the first strand and the second strand are linked by a loop sequence. In some embodiments, the loop sequence is 5'-GUUUUGGCCACUGACUGAC-3' (SEQ ID NO: 60).
[0092] In some embodiments, the present disclosure provides a method for treating a neurodegenerative synucleinopathic disease in a mammal, comprising administering to the mammal an RNAi comprising a first strand comprising a first nucleic acid comprising the sequence 5'-UGGGCACAUUGGAACUGAGCA-3' (SEQ ID NO: 8) and a second strand comprising a second nucleic acid comprising the sequence 5'-UGCUCAGUCAAUGUGCCUA-3' (SEQ ID NO: 37), wherein the first strand and the second strand form a duplex. In some embodiments, the present disclosure provides a method for inhibiting expression of SNCA in a mammal having a neurodegenerative synucleinopathic disease comprising administering to the mammal an RNAi comprising a first strand comprising a first nucleic acid comprising the sequence 5'-UGGGCACAUUGGAACUGAGCA-3' (SEQ ID NO:8) and a second strand comprising a second nucleic acid comprising the sequence 5'-UGCUCAGUCAAUGUGCCUA-3' (SEQ ID NO:37), wherein the first strand and the second strand form a duplex. In some embodiments, the present disclosure provides a method for inhibiting accumulation of SNCA in cells of a mammal having a neurodegenerative synucleinopathic disease, comprising administering to the mammal an RNAi comprising a first strand comprising a first nucleic acid comprising the sequence 5'-5'-UGGGCACAUUGGAACUGAGCA-3'-3' (SEQ ID NO: 8) and a second strand comprising a second nucleic acid comprising the sequence 5'-UGCUCAGUCAAUGUGCCUA-3' (SEQ ID NO: 37), wherein the first strand and the second strand form a duplex. In some embodiments, the miRNA comprises an internal bulge created by deleting two bases (bases 9-10, counting from the start of the passenger strand) from the passenger strand of the miRNA. In some embodiments, the first strand comprises a nucleic acid sequence having a percentage identity greater than about any of 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% to SEQ ID NO: 8. In some embodiments, the second strand comprises a nucleic acid sequence having a percentage identity greater than about any of 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% to SEQ ID NO: 37. In some embodiments, the first strand and the second strand are linked by a loop sequence. In some embodiments, the loop sequence is 5'-GUUUUGGCCACUGACUGAC-3' (SEQ ID NO: 60).
[0093] In some embodiments, the RNAi is a small inhibitory RNA (siRNA), a microRNA (miRNA), or a small hairpin RNA (shRNA). Small inhibitory or interfering RNA (siRNA) is known in the art as a double-stranded RNA molecule of approximately 19-25 (e.g., 19-23) base pairs in length that induces RNAi in cells. Small hairpin RNA (shRNA) is known in the art as an RNA molecule that includes approximately 19-25 (e.g., 19-23) base pairs of double-stranded RNA linked by a short loop (e.g., about 4-11 nucleotides) that induces RNAi in cells.
[0094] In some embodiments, the miRNA comprises a guide sequence that is about 90% identical to SEQ ID NO: 24. In some embodiments, the miRNA comprises a guide sequence that is about 90% identical, 91% identical, 92% identical, 93% identical, 94% identical, 95% identical, 96% identical, 97% identical, 98% identical, 99% identical, or 100% identical to SEQ ID NO: 24.
[0095] In some embodiments, the miRNA comprises a non-guide sequence that is about 90% identical to SEQ ID NO: 24. In some embodiments, the miRNA comprises a non-guide sequence that is about 90% identical, 91% identical, 92% identical, 93% identical, 94% identical, 95% identical, 96% identical, 97% identical, 98% identical, 99% identical, or 100% identical to SEQ ID NO: 53. Any RNAi described herein (e.g., part of a rAAV vector) can be utilized, inter alia, in treating neurodegenerative synucleinopathies. In another embodiment, any RNAi described in Table 1 can be used in treating neurodegenerative synucleinopathies.
[0096] In some embodiments, the miRNA comprises a guide sequence that is about 90% identical to SEQ ID NO: 8. In some embodiments, the miRNA comprises a guide sequence that is about 90% identical, 91% identical, 92% identical, 93% identical, 94% identical, 95% identical, 96% identical, 97% identical, 98% identical, 99% identical, or 100% identical to SEQ ID NO: 8. include.
[0097] In some embodiments, the miRNA comprises a non-guide sequence that is about 90% identical to SEQ ID NO: 37. In some embodiments, the miRNA comprises a non-guide sequence that is about 90% identical, 91% identical, 92% identical, 93% identical, 94% identical, 95% identical, 96% identical, 97% identical, 98% identical, 99% identical, or 100% identical to SEQ ID NO: 37. Any RNAi described herein (e.g., part of a rAAV vector) can be utilized, inter alia, in treating neurodegenerative synucleinopathies. In another embodiment, any RNAi described in Table 1 can be used in treating neurodegenerative synucleinopathies.
[0098] In some embodiments, the first strand and the second strand are connected by RNA that can form a loop structure.As is generally known in the art, an RNA loop structure (such as stem-loop or hairpin) is formed when an RNA molecule comprises two sequences of RNA that base-pair with each other, separated by a sequence of RNA that does not base-pair with each other.For example, when sequences A and C are complementary or partially complementary to each other so that they base-pair with each other, but the bases in sequence B do not base-pair with each other, a loop structure can be formed in RNA molecule ABC.
[0099] In some embodiments, the RNA capable of forming a loop structure comprises 4 to 50 nucleotides. In certain embodiments, the RNA capable of forming a loop structure comprises 13 nucleotides. In certain embodiments, the RNA capable of forming a loop structure comprises the nucleotide sequence of SEQ ID NO: 60. In some embodiments, the vector genome comprises a nucleotide sequence that is at least about any of 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the sequence of SEQ ID NO: 60.
[0100] In some embodiments, recombinant viral particles are delivered by injecting viral particles into the brain. In some embodiments, recombinant viral particles are delivered by injecting viral particles into the striatum. Intrastriatal administration is to deliver recombinant viral particles to the area of the brain, striatum (including putamen and caudate nucleus), which is highly affected by neurodegenerative synucleinopathies. In addition, without wishing to be bound by theory, it is believed that recombinant viral particles (e.g., rAAV particles) injected into the striatum can also be dispersed (e.g., via retrograde transport) to other areas of the brain, such as, but not limited to, projection fields (e.g., cortex or substantia nigra). In some embodiments, recombinant viral particles are delivered by convection-enhanced delivery (e.g., convection-enhanced delivery to the striatum).
[0101] In some aspects, the present disclosure provides a method for treating a neurodegenerative synucleinopathic disease in a mammal, comprising administering to the mammal a pharmaceutical composition of the present disclosure. In some aspects, the present disclosure provides a method for inhibiting accumulation of SNCA in cells of a mammal having a neurodegenerative synucleinopathic disease, comprising administering to the mammal a pharmaceutical composition of the present disclosure. In some aspects, the present disclosure provides a method for inhibiting expression of SNCA in a mammal having a neurodegenerative synucleinopathic disease, comprising administering to the mammal a pharmaceutical composition of the present disclosure. In some embodiments, the SNCA is a mutant SNCA (e.g., a human SNCA mutation including one or more of A53T, E46K, A30P, G51D, H50Q, A53E, A29S, A18T, and duplications and triplicates of the locus). In some embodiments, expression and / or accumulation of wild-type SNCA is also inhibited. As described herein, without wishing to be bound by theory, it is believed that the expression and / or accumulation of mutant SNCA in a mammal having a neurodegenerative synucleinopathic disease is inhibited by administering to the mammal a pharmaceutical composition of the present disclosure. While inhibition of accumulation would be highly beneficial, inhibition of wild-type SNCA expression and / or accumulation in the same mammal as a side effect (e.g., of the RNAi disclosed herein) is believed to be well tolerated (e.g., resulting in few or no unintended side effects).
[0102] In some embodiments, the cell comprises a vector (e.g., a vector comprising an expression construct encoding an RNAi of the present disclosure). In some embodiments, the vector is a rAAV vector. In some embodiments, the vector is a recombinant adenovirus vector, a recombinant lentivirus vector, or a recombinant herpes simplex virus (HSV) vector. In some embodiments, the cell is a cell of the central nervous system (CNS). In some embodiments, the cell is a HEK293 cell.
[0103] In some embodiments, administering an effective amount of recombinant viral particles containing a vector encoding an RNAi of the present disclosure transduces neurons (e.g., striatal neurons, such as spiny cells) at or near the administration site. In some embodiments, any of about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75% or 100% of neurons are transduced. In some embodiments, about 5% to about 100%, about 10% to about 50%, about 10% to about 30%, about 25% to about 75%, about 25% to about 50%, or about 30% to about 50% of neurons are transduced. Methods for identifying neurons transduced by recombinant viral particles expressing miRNAs are known in the art; for example, immunohistochemistry, RNA detection (e.g., qPCR, Northern blotting, RNA-seq, in situ hybridization, etc.) or the use of co-expressed markers such as enhanced green fluorescent protein can be used to detect expression.
[0104] In some embodiments of the present disclosure, the method includes administering to the mammalian brain an effective amount of a recombinant viral particle comprising a vector encoding the RNAi of the present disclosure for treating a mammal, e.g., a human, having a neurodegenerative synucleinopathy. In some embodiments, the composition is injected into one or more locations in the brain to allow expression of the RNAi of the present disclosure in at least neurons. In some embodiments, the composition is injected into any one of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more than 10 locations in the brain. In some embodiments, the composition is injected into the striatum. In some embodiments, the composition is injected into the dorsal striatum. In some embodiments, the composition is injected into the putamen. In some embodiments, the composition is injected into the caudate nucleus. In some embodiments, the composition is injected into the putamen and caudate nucleus. In some embodiments, the route of administration includes CSF delivery by intracerebroventricular, intracisternal, or intrathecal injection. In some embodiments, administration also includes intravenous delivery of the viral vector.
[0105] In some embodiments, the recombinant viral particles are administered to one hemisphere of the brain. In some embodiments, the recombinant viral particles are administered to both hemispheres of the brain.
[0106] In some embodiments, the recombinant viral particles are administered to more than one location, either simultaneously or sequentially, hi some embodiments, the multiple injections of recombinant viral particles are spaced apart by no more than 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 9 hours, 12 hours, or 24 hours.
[0107] In some embodiments, the present disclosure provides a method for treating a human having a neurodegenerative synucleinopathic disease by administering an effective amount of a pharmaceutical composition comprising a recombinant viral vector encoding an RNAi of the present disclosure to inhibit the activity of mutant SNCA. In some embodiments, the pharmaceutical composition comprises one or more pharma- ceutically acceptable excipients.
[0108] In some embodiments, the method comprises administering an effective amount of a pharmaceutical composition comprising a recombinant viral vector encoding an RNAi of the present disclosure to suppress the activity of a mutant SNCA. In some embodiments, the viral titer of the viral particles (e.g., rAAV particles) is at least about 5×10 12 , 6×10 12 , 7×10 12 , 8×10 12 , 9×10 12 , 10×10 12 , 11×10 12 , 15×10 12 , 20×10 12 , 25×10 12 , 30×10 12 , or 50×10 12 In some embodiments, the viral titer of the viral particles (e.g., rAAV particles) is about 5×10 12 From 16×10 12 , 6×10 12From 7×10 12 , 7×10 12 From 8×10 12 , 8×10 12 From 9×10 12 , 9×10 12 From 10×10 12 , 10×10 12 From 11×10 12 , 11×10 12 From 15×10 12 , 15×10 12 From 20×10 12 , 20×10 12 From 25×10 12 , 25×10 12 From 30×10 12 , 30×10 12 From 50×10 12 , or 50×10 12 From 100 x 10 12 In some embodiments, the viral titer of the viral particles (e.g., rAAV particles) is about 5×10 12 From 10×10 12 , 10×10 12 From 25×10 12 , or 25 × 10 12 From 50×10 12 In some embodiments, the viral titer of the viral particles (e.g., rAAV particles) is at least about 5×10 9 , 6×10 9 , 7×10 9 , 8×10 9 , 9×10 9 , 10×10 9 , 11×10 9 , 15×10 9 , 20×10 9 , 25×10 9 , 30×10 9 , or 50×10 9 In some embodiments, the viral titer of the viral particles (e.g., rAAV particles) is about 5×10 9 From 6×10 9 , 6×10 9 From 7×10 9, 7×10 9 From 8×10 9 , 8×10 9 From 9×10 9 , 9×10 9 From 10×10 9 , 10×10 9 From 11×10 9 , 11×10 9 From 15×10 9 , 15×10 9 From 20×10 9 , 20×10 9 From 25×10 9 , 25×10 9 From 30×10 9 , 30×10 9 From 50×10 9 or 50×10 9 From 100 x 10 9 In some embodiments, the viral titer of the viral particles (e.g., rAAV particles) is about 5×10 9 From 10×10 9 , 10×10 9 From 15×10 9 , 15×10 9 From 25×10 9 , or 25 × 10 9 From 50×10 9 In some embodiments, the viral titer of the viral particles (e.g., rAAV particles) is at least about 5×10 10 , 6×10 10 , 7×10 10 , 8×10 10 , 9×10 10 , 10×10 10 , 11×10 10 , 15×10 10 , 20×10 10 , 25×10 10 , 30×10 10 , 40×10 10 , or 50×10 10 In some embodiments, the viral titer of the viral particles (e.g., rAAV particles) is at least about 5×10 infectious units / mL. 10 From 6×1010 , 6×10 10 From 7×10 10 , 7×10 10 From 8×10 10 , 8×10 10 From 9×10 10 , 9×10 10 From 10×10 10 , 10×10 10 From 11×10 10 , 11×10 10 From 15×10 10 , 15×10 10 From 20×10 10 , 20×10 10 From 25×10 10 , 25×10 10 From 30×10 10 , 30×10 10 From 40×10 10 , 40×10 10 From 50×10 10 , or 50×10 10 From 100 x 10 10 In some embodiments, the viral titer of the viral particles (e.g., rAAV particles) is at least about 5×10 infectious units / mL. 10 From 10×10 10 , 10×10 10 From 15×10 10 , 15×10 10 From 25×10 10 , or 25 × 10 10 From 50×10 10 infectious units / mL.
[0109] In some embodiments, the dose of viral particles administered to an individual is at least about 1 x 10 per kg of body weight. 8 ~Approx. 1×10 13 In some embodiments, the dose of viral particles administered to an individual is about 1 x 10 per kg of body weight. 8 ~Approx. 1×10 13 Either of the genome copies.
[0110] In some embodiments, the total amount of viral particles administered to an individual is at least about 1×10 9 ~Approx. 1×10 14 In some embodiments, the total amount of viral particles administered to an individual is about 1×10 9 ~Approx. 1×10 14 Either of the genome copies.
[0111] In some embodiments of the present disclosure, the volume of the composition injected into the striatum is greater than or equal to approximately any one of 1 μl, 2 μl, 3 μl, 4 μl, 5 μl, 6 μl, 7 μl, 8 μl, 9 μl, 10 μl, 15 μl, 20 μl, 25 μl, 50 μl, 75 μl, 100 μl, 200 μl, 300 μl, 400 μl, 500 μl, 600 μl, 700 μl, 800 μl, 900 μl, or 1 mL, or any amount therebetween.
[0112] In some embodiments, a first volume of the composition is injected into a first region of the brain, and a second volume of the composition is injected into a second region of the brain.For example, in some embodiments, a first volume of the composition is injected into the caudate nucleus, and a second volume of the composition is injected into the putamen. In some embodiments, a 1X volume of the composition is injected into the caudate nucleus and a 1.5X, 2X, 2.5X, 3X, 3.5X, or 4X volume of the composition is injected into the putamen, where X is approximately any one of 1 μl, 2 μl, 3 μl, 4 μl, 5 μl, 6 μl, 7 μl, 8 μl, 9 μl, 10 μl, 15 μl, 20 μl, 25 μl, 50 μl, 75 μl, 100 μl, 200 μl, 300 μl, 400 μl, 500 μl, 600 μl, 700 μl, 800 μl, 900 μl, or 1 mL, or any amount therebetween.
[0113] The compositions of the present disclosure (e.g., recombinant viral particles comprising a vector encoding an RNAi of the present disclosure) can be used either alone or in combination with one or more additional therapeutic agents for treating neurodegenerative synucleinopathies. The interval between sequential administrations may be on the order of at least minutes, hours, or days (or alternatively less).
[0114] Any RNAi, expression construct, vector or cell described in this disclosure can be used in any of the above methods.In some embodiments, any RNAi disclosed in Table 1, expression construct, vector or cell comprising the RNAi of Table 1 can be used in any of the above methods.
[0115] V. RNAi Expression Constructs and Vectors The present disclosure provides expression constructs, vectors and viral particles for expression of the RNAi described herein.
[0116] In some embodiments, the nucleic acid encoding the RNAi of the present disclosure comprises a heterologous miRNA scaffold. In some embodiments, the use of a heterologous miRNA scaffold regulates miRNA expression; for example, it is used to increase miRNA expression or decrease miRNA expression. Any miRNA scaffold known in the art can be used. In some embodiments, the miRNA scaffold is derived from the miR-155 scaffold (see, for example, Lagos-Quintana, M. et al. (2002) Curr. Biol. 12:735-9 and Invitrogen™ BLOCK-iT™ Pol II miR RNAi Expression Vector Kit from Life Technologies, Thermo Fisher Scientific; Waltham, MA). In some embodiments, the nucleic acid encoding the RNAi of the present disclosure comprises a miRNA scaffold. In some embodiments, the miRNA scaffold is a scaffold of the sequence [ka] where the miRNA is inserted between the bold gc residues.
[0117] In some embodiments, the scaffold miRNA has the sequence [ka] where underlined normal text represents the 5' flank, italic text represents the guide sequence, bold text represents the loop, underlined italics represents the non-guide sequence, and normal text represents the 3' flank.
[0118] In some embodiments, RNAi targets RNA that encodes a polypeptide associated with neurodegenerative synucleinopathies. In some embodiments, the polypeptide is alpha-synuclein. Without wishing to be bound by theory, it is believed that RNAi can be used to reduce or eliminate the expression and / or activity of a polypeptide whose gain of function is associated with neurodegenerative synucleinopathies. Non-limiting examples of neurodegenerative synucleinopathies of the present disclosure that can be treated by therapeutic polypeptides or therapeutic nucleic acids of the present disclosure include Parkinson's disease (SNCA), multiple system atrophy or MSA (SNCA), and dementia with Lewy bodies (SNCA) (exemplary genes targeted or delivered are given in brackets for each disorder).
[0119] In some embodiments, the transgene (eg, an RNAi of the present disclosure) is operably linked to a promoter. Exemplary promoters include, but are not limited to, the cytomegalovirus (CMV) immediate early promoter, the RSV LTR, the MoMLV LTR, the phosphoglycerate kinase-1 (PGK) promoter, the simian virus 40 (SV40) promoter and the CK6 promoter, the transthyretin promoter (TTR), the TK promoter, the tetracycline responsive promoter (TRE), the HBV promoter, the hAAT promoter, the LSP promoter, the chimeric liver specific promoter (LSP), the E2F promoter, the telomerase (hTERT) promoter; the cytomegalovirus enhancer / chicken beta-actin / rabbit beta-globin promoter (CAG promoter; Niwa et al., Gene, 1991, 108(2):193-9), and the elongation factor 1-alpha promoter (EF1-alpha) promoter (Kim et al., Gene, 1990, 91(2):217-23 and Guo et al., Gene Ther., 1996, 3(9):802-10). In some embodiments, the promoter comprises a human β-glucuronidase promoter or a cytomegalovirus enhancer linked to a chicken β-actin (CBA) promoter. The promoter may be a constitutive, inducible or repressible promoter. In some embodiments, the present disclosure provides a recombinant vector comprising a nucleic acid encoding a heterologous transgene of the present disclosure operably linked to a CBA promoter. Exemplary promoters and descriptions can be found, for example, in US Pregrant Publication No. 20140335054. In some embodiments, the promoter is a CBA promoter, a minimal CBA promoter, a CMV promoter or a GUSB promoter. In some embodiments, the promoter is a hEF1a promoter.
[0120] Examples of constitutive promoters include, but are not limited to, the retroviral Rous sarcoma virus (RSV) LTR promoter (optionally with the RSV enhancer), the cytomegalovirus (CMV) promoter (optionally with the CMV enhancer) [see, e.g., Boshart et al., Cell, 41:521-530 (1985)], the SV40 promoter, the dihydrofolate reductase promoter, the 13-actin promoter, the phosphoglycerol kinase (PGK) promoter, and the EF1 promoter [Invitrogen].
[0121] Inducible promoters allow for the control of gene expression and may be controlled by exogenously supplied compounds, environmental factors such as temperature, or the presence of specific physiological conditions, e.g., acute phase of cells, a particular differentiation state, or only in replicating cells. Inducible promoters and inducible systems are available from a variety of commercial sources, including, but not limited to, Invitrogen, Clontech, and Ariad. Many other systems have been described and can be readily selected by one of skill in the art. Examples of inducible promoters controlled by exogenously supplied promoters include the zinc-inducible sheep metallothionein (MT) promoter, the dexamethasone (Dex)-inducible mouse mammary tumor virus (MMTV) promoter, the T7 polymerase promoter system (WO 98 / 10088); the ecdysone insect promoter (No et al., Proc. Natl. Acad. Sci. USA, 93:3346-3351 (1996)), the tetracycline repression system (Gos See, for example, Gossen et al., Proc. Natl. Acad. Sci. USA, 89:5547-5551 (1992)), the tetracycline-inducible system (Gossen et al., Science, 268:1766-1769 (1995); see also Harvey et al., Curr. Opin. Chem. Biol., 2:512-518 (1998)), the RU486-inducible system (Wang et al., Nat. Biotech., 15:239-243 (1997) and Wang et al., Gene Ther., 4:432-441 (1997)), and the rapamycin-inducible system (Magari et al., J. Clin. Invest., 100:2865-2872 (1997)). Yet other types of inducible promoters that may be useful in this context are those that are regulated by specific physiological conditions, such as temperature, acute phase, a particular differentiation state of the cell, or that are regulated only in replicating cells.
[0122] In another embodiment, it is expected that the promoter native to the transgene, or a fragment thereof, is used. When it is desired that the expression of the transgene mimics the native expression, the native promoter may be preferred. When the expression of the transgene must be controlled temporally or developmentally, or in a tissue-specific manner, or in response to a specific transcriptional stimulus, the native promoter may be used. In a further embodiment, other native expression control elements, such as enhancer elements, polyadenylation sites, or Kozak consensus sequences, can also be used to mimic the native expression.
[0123] In some embodiments, the regulatory sequence confers tissue-specific gene expression. In some cases, the tissue-specific regulatory sequence binds to tissue-specific transcription factors that induce transcription in a tissue-specific manner. Such tissue-specific regulatory sequences (e.g., promoters, enhancers, etc.) are well known in the art. Exemplary tissue-specific regulatory sequences include, but are not limited to, the following tissue-specific promoters: neuronal, e.g., the neuron-specific enolase (NSE) promoter (Andersen et al., Cell. Mol. Neurobiol., 13:503-15 (1993)), the neurofilament light chain gene promoter (Piccioli et al., Proc. Natl. Acad. Sci. USA, 88:5611-5 (1991)), and the neuron-specific vgf gene promoter (Piccioli et al., Neuron, 15:373-84 (1995)). In some embodiments, the tissue-specific promoter is a promoter of a gene selected from neuronal nucleus (NeuN), glial fibrillary acidic protein (GFAP), adenomatous polyposis coli (APC), and ionized calcium-binding adaptor molecule 1 (Iba-1). Other suitable tissue-specific promoters will be apparent to those skilled in the art. In some embodiments, the promoter is a chicken beta-actin promoter.
[0124] In some embodiments, the promoter expresses the heterologous nucleic acid in cells of the CNS. As such, in some embodiments, the therapeutic polypeptide or therapeutic nucleic acid of the present disclosure can be used to treat disorders of the CNS. In some embodiments, the promoter expresses the heterologous nucleic acid in cells of the brain. The cells of the brain can refer to any brain cell known in the art, including, but not limited to, neurons (e.g., sensory neurons, motor neurons, interneurons, dopaminergic neurons, medium spiny neurons, cholinergic neurons, GABAergic neurons, pyramidal neurons, etc.), glial cells (e.g., microglia, astroglia, astrocytes, oligodendrocytes, ependymal cells, radial glia, etc.), brain parenchymal cells, microglia, ependymal cells, and / or Purkinje cells. In some embodiments, the promoter expresses the heterologous nucleic acid in neurons and / or glial cells. In some embodiments, the neurons are medium spiny neurons of the caudate nucleus, medium spiny neurons of the putamen, neurons of cortical layer IV and / or neurons of cortical layer V.
[0125] A variety of promoters for expressing transcripts (e.g., heterologous transgenes) in CNS cells, brain cells, neurons, and glial cells are known in the art and are described herein. Such promoters may include control sequences that are typically linked to a selected gene or heterologous control sequences. In many cases, useful heterologous control sequences include sequences derived from sequences encoding mammalian or viral genes. Examples include, but are not limited to, SV40 early promoter, mouse mammary tumor virus LTR promoter, adenovirus major late promoter (AdMLP), herpes simplex virus (HSV) promoter, cytomegalovirus (CMV) promoter, such as the CMV immediate early promoter region (CMVIE), Rous sarcoma virus (RSV) promoter, synthetic promoters, hybrid promoters, and the like. In addition, sequences derived from non-viral genes, such as the mouse metallothionein gene, may also be used. Such promoter sequences are commercially available, for example, from Stratagene (San Diego, Calif.). CNS-specific promoters and inducible promoters may also be used. Examples of CNS-specific promoters include, but are not limited to, promoters isolated from CNS-specific genes such as myelin basic protein (MBP), glial fibrillary acidic protein (GFAP), and neuron-specific enolase (NSE). Examples of inducible promoters include DNA response elements for ecdysone, tetracycline, metallothionein, and hypoxia, among others.
[0126] The present disclosure anticipates the use of recombinant virus genome to introduce or package one or more nucleic acid sequences encoding RNAi into AAV virus particles, as described herein.Recombinant virus genome can include any element for establishing the expression of RNAi, such as promoter, heterologous nucleic acid, ITR, ribosome binding element, terminator, enhancer, selection marker, intron, polyA signal, and / or replication origin.In some embodiments, rAAV vector comprises one or more of enhancer, splice donor / splice acceptor pair, matrix attachment site, or polyadenylation signal.
[0127] In some embodiments, an effective amount of rAAV particles comprising a vector encoding an RNAi Administration of transduces cells (e.g., CNS cells, brain cells, neurons, and / or glial cells) at or near the site of administration (e.g., striatum and / or cortex) or more distal to the site of administration. In some embodiments, greater than about any of 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, or 100% of the neurons are transduced. In some embodiments, about 5% to about 100%, about 10% to about 50%, about 10% to about 30%, about 25% to about 75%, about 25% to about 50%, or about 30% to about 50% of the neurons are transduced. Methods for identifying neurons that have been transduced by recombinant viral particles expressing miRNAs are known in the art; for example, immunohistochemistry, RNA detection (e.g., qPCR, Northern blotting, RNA-seq, in situ hybridization, etc.) or the use of co-expressed markers such as enhanced green fluorescent protein can be used to detect expression.
[0128] In some embodiments, the present disclosure provides a virus particle that comprises recombinant self-complementary genome (e.g., self-complementary rAAV vector). AAV virus particles with self-complementary vector genome and the method of using self-complementary AAV genome are described in U.S. Patent Nos. 6,596,535; 7,125,717; 7,465,583; 7,785,888; 7,790,154; 7,846,729; 8,093,054; and 8,361,457; and Wang Z. et al., (2003) Gene Ther 10:2105-2111, each of which is incorporated herein by reference in its entirety. It is expected that the rAAV that comprises self-complementary genome will rapidly form a double-stranded DNA molecule by its partially complementary sequence (e.g., the complementary coding and non-coding strands of heterologous nucleic acid). In some embodiments, the vector comprises a first nucleic acid sequence encoding a heterologous nucleic acid and a second nucleic acid sequence encoding a complement of that nucleic acid, wherein the first nucleic acid sequence is capable of intrastrand base pairing with the second nucleic acid sequence over most or all of its length.
[0129] In some embodiments, the first heterologous nucleic acid sequence encoding RNAi and the second heterologous nucleic acid sequence encoding the complement of RNAi are linked by a mutated ITR (e.g., the right ITR). In some embodiments, the ITR comprises the polynucleotide sequence 5'-CACTCCCTCTCTGCGCGCTCGCTCGCTCACTGAGGCCGGGCGACCAAAGGTCGCCCACGCCCGGGCTTTGCCCGGGCG-3' (SEQ ID NO: 69). The mutated ITR comprises a deletion of the D region that includes a terminal resolution sequence. As a result, during replication of the AAV viral genome, the rep protein is not expected to cleave the viral genome at the mutated ITR, and as such, a recombinant viral genome is expected to be packaged in the viral capsid that includes the following in 5' to 3' order: AAV ITR, the first heterologous polynucleotide sequence that includes the control sequence, the mutated AAV ITR, the first heterologous polynucleotide, and the second heterologous polynucleotide in the reverse direction to the third AAV ITR.
[0130] VI. VIRAL PARTICLES AND METHODS FOR PRODUCING VIRAL PARTICLES The present disclosure provides, inter alia, recombinant viral particles comprising nucleic acids encoding the RNAi of the present disclosure and methods of using same to treat a disease or disorder, such as a neurodegenerative synucleinopathic disease, in a mammal.
[0131] Virus particles The present disclosure provides a viral particle comprising the RNAi disclosed herein. In some embodiments, the present disclosure provides a viral particle for delivering the RNAi disclosed herein. For example, the present disclosure provides a recombinant viral particle for delivering RNAi to treat disease or disorder in a mammal; for example, a recombinant viral particle for delivering RNAi to treat neurodegenerative diseases or disorders in a mammal; The present invention provides a method of using rAAV particles containing RNAi to treat degenerative synucleinopathies. In some embodiments, the recombinant viral particle is a recombinant AAV particle. In some embodiments, the viral particle is a recombinant AAV particle that contains a nucleic acid containing a sequence of the RNAi of the present disclosure, flanked by one or two ITRs. The nucleic acid is encapsidated in the AAV particle. The AAV particle also contains a capsid protein. In some embodiments, the nucleic acid contains a coding sequence of interest (e.g., the nucleic acid of the RNAi of the present disclosure), a control sequence including a transcription start and termination sequence, operably linked to the component in the transcription direction, thereby forming an expression construct. The expression construct has at least one functional AAV ITR sequence at the 5' and 3' ends. By "functional AAV ITR sequence" is meant an ITR sequence function for the purpose of rescue, replication and packaging of AAV virions. See Davidson et al., PNAS, 2000, 97(7):3428-32; Passini et al., J. Virol., 2003, 77(12):7034-40; and Pechan et al., Gene Ther., 2009, 16:10-16. To implement some embodiments of the present disclosure, the recombinant vector contains at least all of the sequences of AAV essential for encapsidation and the physical structure for infection by rAAV. The ITRs of AAV for use in the vectors of the present disclosure may not have a wild-type nucleotide sequence (e.g., as described in Kotin, Hum. Gene Ther., 1994, 5:793-801), may be altered by nucleotide insertion, deletion or substitution, or may be derived from any of a number of AAV serotypes. Over 40 AAV serotypes are known to date, and new serotypes and variants of existing serotypes continue to be identified. See Gao et al., PNAS, 2002, 99(18):11854-6; Gao et al., PNAS, 2003, 100(10):6081-6; and Bossis et al., J. Virol., 2003, 77(12):6799-810. The use of any AAV serotype is considered within the scope of this disclosure. In some embodiments, the rAAV vector is a vector derived from an AAV serotype, such as, but not limited to, AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAVrh8, AAVrh8R, AAV9, AAV10, AAVrh10, AAV11, AAV12, AAV2R471A, AAV DJ, caprine AAV, bovine AAV, or mouse AAV capsid serotype. In some embodiments, the nucleic acid in the AAV comprises ITR such as AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAVrh8, AAVrh8R, AAV9, AAV10, AAVrh10, AAV11, AAV12, AAV2R471A, AAV DJ, caprine AAV, bovine AAV, or mouse AAV capsid serotype.In some embodiments, the nucleic acid in the AAV further encodes the RNAi described herein.In some embodiments, the rAAV particle comprises AAV1, AAV2HBKO capsid (e.g., as described in WO2015168666), AAV9 capsid, PHP.B capsid, PHP.eB capsid, or Olig001 capsid.
[0132] For example, the nucleic acid in the AAV can further encode an RNAi comprising at least one ITR of any AAV serotype contemplated in the present invention and comprising a first strand and a second strand, where a) the first strand and the second strand form a duplex; b) the first strand comprises a guide region, and c) the second strand comprises a non-guide region, the non-guide region comprising a deletion of two nucleotides at bases 9 and 10 to create a bulge in the guide strand. In some embodiments, the rAAV comprises a first strand comprising a first nucleic acid comprising the sequence 5'-UGCUCUUUGGUCUUCUCAGCC-3' (SEQ ID NO:24) and a second strand comprising a second nucleic acid comprising the sequence 5'-GGCUGAGAACCAAAGAGUA-3' (SEQ ID NO:53). In some embodiments, the rAAV comprises a first strand comprising a first nucleic acid comprising the sequence 5'-UGGGCACAUUGGAACUGAGCA-3' (SEQ ID NO:8) and a second nucleic acid comprising the sequence 5'-UGCUCAGUCAAUGUGCCUA-3' (SEQ ID NO:37). In some embodiments, the nucleic acid in the AAV comprises a nucleic acid from 5' to 3' that encodes the following: an ITR (e.g., an ITR of AAV2), a promoter, a nucleic acid encoding an RNAi disclosed herein, a polyadenylation signal, and an ITR of AAV (e.g., an ITR of AAV2). In some embodiments, the nucleic acid in the AAV comprises a nucleic acid from 5' to 3' that encodes the following: an ITR (e.g., an ITR of AAV2), a promoter, a nucleic acid encoding an RNAi comprising a first strand comprising a first nucleic acid comprising the sequence 5'-UGCUCUUUGGUCUUCUCAGCC-3' (SEQ ID NO: 24) and a second strand comprising a second nucleic acid comprising the sequence 5'-GGCUGAGAACCAAAGAGUA-3' (SEQ ID NO: 53), a polyadenylation signal, and an ITR of AAV (e.g., an ITR of AAV2). In some embodiments, the nucleic acid in the AAV comprises a nucleic acid from 5' to 3' that codes for the following: ITR (e.g., ITR of AAV2), a promoter, a nucleic acid encoding an RNAi comprising a first strand comprising a first nucleic acid comprising the sequence 5'-UGGGCACAUUGGAACUGAGCA-3' (SEQ ID NO: 8) and a second strand comprising a second nucleic acid comprising the sequence 5'-UGCUCAGUCAAUGUGCCUA-3' (SEQ ID NO: 37), a polyadenylation signal, and an ITR of AAV (e.g., ITR of AAV2). In some embodiments, the nucleic acid in the AAV comprises a nucleic acid from 5' to 3' that codes for the following: ITR (e.g., ITR of AAV2), a CBA promoter, a nucleic acid encoding an RNAi disclosed herein, a polyadenylation signal (e.g., bovine growth hormone polyA), and an ITR of AAV (e.g., ITR of AAV2). In some embodiments, the RNAi is selected from Table 1.In some embodiments, the nucleic acid in the AAV comprises a nucleic acid encoding from 5' to 3': an ITR (e.g., an ITR of AAV2), a CBA promoter, a nucleic acid encoding an RNAi comprising a first strand comprising a first nucleic acid comprising the sequence 5'-UGCUCUUUGGUCUUCUCAGCC-3' (SEQ ID NO:24) and a second strand comprising a second nucleic acid comprising the sequence 5'-GGCUGAGAACCAAAGAGUA-3' (SEQ ID NO:53), a polyadenylation signal (e.g., bovine growth hormone polyA), and an ITR of an AAV (e.g., an ITR of AAV2). In some embodiments, the nucleic acid in the AAV comprises a nucleic acid encoding from 5' to 3' the following: an ITR (e.g., an ITR of AAV2), a CBA promoter, a nucleic acid encoding an RNAi comprising a first strand comprising a first nucleic acid comprising the sequence 5'-UGGGCACAUUGGAACUGAGCA-3' (SEQ ID NO:8) and a second strand comprising a second nucleic acid comprising the sequence 5'-UGCUCAGUCAAUGUGCCUA-3' (SEQ ID NO:37), a polyadenylation signal (e.g., bovine growth hormone polyA), and an ITR of an AAV (e.g., an ITR of AAV2). In some embodiments, the first and second strands are selected from Table 1.
[0133] In some embodiments, the vector may include a stuffer nucleic acid. In some embodiments, the stuffer nucleic acid may code for green fluorescent protein. In some embodiments, the stuffer nucleic acid may be located between the promoter and the nucleic acid that codes for RNAi. In some embodiments, the stuffer nucleic acid is the A1AT stuffer nucleic acid.
[0134] In some embodiments, the nucleic acid in the AAV comprises a nucleic acid of SEQ ID NO: 65. In some embodiments, the nucleic acid in the AAV comprises a nucleic acid that is at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 65. In further embodiments, the rAAV particle comprises an AAV1, AAV2, AAV3, AAV4, AAV5, AA6, AAV7, AAV8, AAV9, AAVrh.8, AAVrh8R, AAVrh.10, AAV11, AAV12 capsid protein, or a mutant of these capsid proteins. In some embodiments, the mutant capsid protein maintains the ability to form an AAV capsid. In some embodiments, the rAAV particle comprises an AAV5 tyrosine mutant capsid (Zhong L. et al., (2008) Proc Natl Acad S ci USA 105(22):7827-7832). In further embodiments, the rAAV particles comprise capsid proteins of AAV serotypes from clades A-F (Gao, et al., J. Virol. 2004, 78(12):6381).
[0135] Different AAV serotypes are used to optimize transduction of specific target cells or target specific cell types within a specific target tissue (e.g., diseased tissue). rAAV particles may contain viral proteins and viral nucleic acids of the same serotype or mixed serotypes. For example, in some embodiments, rAAV particles may contain AAV1 capsid protein and at least one ITR of AAV2, or rAAV particles may contain AAV2 capsid protein and at least one ITR of AAV1. Any combination of AAV serotypes for rAAV particle production is provided herein as if each combination were explicitly stated herein. In some embodiments, the present invention provides rAAV particles comprising the rAAV vector of the present disclosure (e.g., an expression construct comprising a nucleic acid encoding an RNAi of the present disclosure) flanked by an AAV1 capsid and at least one ITR of AAV2. In some embodiments, the present invention provides rAAV particles comprising an AAV2 capsid. In some embodiments, the rAAV particles comprise an AAV1, an AAV2HBKO capsid (e.g., as described in WO2015168666), an AAV9 capsid, a PHP.B capsid, a PHP.eB capsid, or an Olig001.
[0136] In some embodiments, the present invention provides a virus particle comprising recombinant self-complementary genome.The AAV virus particle with self-complementary genome and the method of using self-complementary AAV genome are described in U.S. Patent No. 6,596,535; No. 7,125,717; No. 7,465,583; No. 7,785,888; No. 7,790,154; No. 7,846,729; No. 8,093,054; and No. 8,361,457; and Wang Z. et al. (2003) Gene Ther 10:2105-2111, each of which is incorporated by reference in its entirety.The rAAV comprising self-complementary genome will rapidly form double-stranded DNA molecule by its partially complementary sequence (e.g., the complementary coding and non-coding strands of transgene). In some embodiments, the present invention provides an AAV virus particle comprising an AAV genome, wherein the rAAV genome comprises a first heterologous polynucleotide sequence (e.g., the RNAi of the present disclosure) and a second heterologous polynucleotide sequence (e.g., the antisense strand of the RNAi of the present disclosure), and the first heterologous polynucleotide sequence can form intrastrand base pairs with the second polynucleotide sequence over most or all of its length.In some embodiments, the first heterologous polynucleotide sequence and the second heterologous polynucleotide sequence are linked by a sequence that facilitates intrastrand base pairing; for example, a hairpin DNA structure. Hairpin structures are known in the art, for example, in miRNA or siRNA molecules.In some embodiments, the first heterologous polynucleotide sequence and the second heterologous polynucleotide sequence are linked by a mutated ITR (e.g., the right ITR). In some embodiments, the ITR comprises the polynucleotide sequence 5'-ttggccactccctctctgcgcgctcgctcgctcactgaggccgcccgggcaaagcccgggcgtcgggcgacctttggtcgcccggcctcagtgagcgagcgagcgcgcagagagggagtggccaactccatcactaggggttcct-3' (SEQ ID NO: 70). The mutated ITR comprises a deletion of the D region including the terminal resolution sequence.As a result, during replication of the AAV viral genome, the rep protein is not expected to cleave the viral genome at the mutated ITR, and as such, when a recombinant viral genome containing, in 5' to 3' order: an AAV ITR, a first heterologous polynucleotide sequence encompassing a regulatory sequence, a mutated AAV ITR, the first heterologous polynucleotide, and a second heterologous polynucleotide in the reverse orientation to the third AAV ITR, is packaged into the viral capsid. In some embodiments, the present invention provides an AAV viral particle comprising a recombinant viral genome comprising a functional AAV2 ITR, a first polynucleotide sequence encoding an RNAi of the present disclosure, a mutant AAV2 ITR comprising a deletion of the D region and lacking a functional terminal resolution sequence, a second polynucleotide sequence comprising a sequence complementary to the sequence of the first polynucleotide sequence encoding an RNAi of the present disclosure, and a functional AAV2 ITR.
[0137] Production of viral particles rAAV particles can be produced using methods known in the art.See, for example, U.S. Patent Nos. 6,566,118; 6,989,264; and 6,995,006. In carrying out the present invention, host cells for producing rAAV particles include mammalian cells, insect cells, plant cells, microorganisms and yeast. Host cells can also be packaging cells in which AAV rep and cap genes are stably maintained in the host cell, or producer cells in which AAV vector genomes are stably maintained. Exemplary packaging and producer cells are derived from 293, A549 or HeLa cells. AAV vectors are purified and formulated using standard techniques known in the art.
[0138] Methods known in the art for producing rAAV vectors include, but are not limited to, transfection, production of stable cell lines, and production systems of infectious hybrid viruses such as adenovirus-AAV hybrids, herpesvirus-AAV hybrids (Conway, J. E. et al., (1997) J. Virology 71(11):8780-8789), and baculovirus-AAV hybrids. All rAAV production cultures for producing rAAV viral particles require 1) a suitable host cell, such as a human-derived cell line, such as HeLa, A549, or 293 cells, or an insect-derived cell line, such as SF-9 in the case of baculovirus production systems; 2) suitable helper virus functions provided by wild-type or mutant adenovirus (e.g., temperature-sensitive adenovirus), herpesvirus, baculovirus, or a plasmid construct providing helper functions; 3) AAV rep and cap genes and gene products; 4) nucleic acid flanked by at least one AAV ITR sequence (e.g., therapeutic nucleic acid); and 5) suitable media and media components that support rAAV production. In some embodiments, the AAV rep and cap gene products may be from any AAV serotype. Generally, but not necessarily, the AAV rep gene product has the same serotype as the ITRs of the rAAV vector genome, so long as the rep gene product functions to replicate and package the rAAV genome. Suitable media known in the art can be used to produce rAAV vectors, including, but not limited to, media produced by Hyclone Laboratories and JRH, such as modified Eagle medium (MEM), Dulbecco's modified Eagle medium (DMEM), and the like, as described in U.S. Patent No. 6,566,118, and custom formulations such as Sf-900 II SFM medium as described in U.S. Patent No. 6,723,551, each of which is incorporated herein by reference in its entirety, particularly with respect to custom media formulations for use in the production of recombinant AAV vectors.In some embodiments, the helper functions of AAV are provided by adenovirus or HSV, hi some embodiments, the helper functions of AAV are provided by baculovirus and the host cell is an insect cell (e.g., a Spodoptera frugiperda (Sf9) cell).
[0139] In some embodiments, the rAAV particles can be produced by a triple transfection method, such as the exemplary triple transfection method set forth below. Briefly, a plasmid containing the rep and capsid genes may be transfected (e.g., using the calcium phosphate method) into a cell line (e.g., HEK-293 cells) along with a helper adenovirus plasmid, and the virus may be harvested and optionally purified. As such, in some embodiments, rAAV particles are produced by triple transfection of a host cell with nucleic acid encoding an rAAV vector, nucleic acid encoding AAV rep and cap, and nucleic acid encoding AAV helper virus functions, the transfection of the nucleic acids into the host cell generating a host cell capable of producing rAAV particles.
[0140] In some embodiments, rAAV particles can be produced by producer cell line methods, such as the exemplary producer cell line methods shown below (see also those referenced in Martin et al., (2013) Human Gene Therapy Methods 24:253-269). Briefly, a cell line (e.g., a HeLa cell line) can be stably transfected with a plasmid containing the rep gene, the capsid gene, and a promoter-heterologous nucleic acid sequence. The cell line can be screened to select a lead clone for rAAV production, which can then be expanded into a production bioreactor and infected with adenovirus (e.g., wild-type adenovirus) as a helper to initiate rAAV production. The virus can then be harvested, the adenovirus can be inactivated (e.g., by heat) and / or removed, and the rAAV particles can be purified. As such, in some embodiments, rAAV particles were produced by a producer cell line containing one or more of nucleic acid encoding the rAAV vector, nucleic acid encoding AAV rep and cap, and nucleic acid encoding AAV helper virus functions.
[0141] In some aspects, a method for producing any of the rAAV particles disclosed herein is provided, comprising: (a) culturing a host cell under conditions in which the rAAV particles are produced, the host cell comprising (i) one or more AAV packaging genes, each of which encodes an AAV replication and / or encapsidation protein; (ii) a rAAV provector comprising a nucleic acid encoding the RNAi of the present disclosure described herein, flanked by at least one AAV ITR, and (iii) AAV helper function; and (b) recovering the rAAV particles produced by the host cell. In some embodiments, the RNAi comprises the nucleotide sequence of SEQ ID NO: 61 (FIG. 1A) or SEQ ID NO: 63 (FIG. 1B). In some embodiments, the at least one AAV ITR is selected from the group consisting of AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAVrh8, AAVrh8R, AAV9, AAV10, AAVrh10, AAV11, AAV12, AAV2R471A, AAV DJ, caprine AAV, bovine AAV, or mouse AAV capsid serotype ITRs, and the like. In some embodiments, the encapsidation protein is selected from the group consisting of AAV1, AAV2, AAV3, AAV4, AAV5, AAV6 (e.g., a wild-type AAV6 capsid, or a variant AAV6 capsid, e.g., ShH10, as described in U.S. Pre-Grant Publication No. 2012 / 0164106), AAV7, AAV8, AAVrh8, AAVrh8R, AAV9 (e.g., a wild-type AAV9 capsid, or a modified AAV9 capsid, as described in U.S. Pre-Grant Publication No. 2013 / 0323226), AAV10, AAVrh10, AAV11, AAV12, a tyrosine capsid mutant, a heparin-binding capsid mutant, an AAV2R471A capsid, an AAVAAV2 / 2-7m8 capsid, an AAV DJ capsids (e.g., AAV-DJ / 8 capsids, AAV-DJ / 9 capsids, or any other capsids described in U.S. Pregrant Publication No. 2012 / 0066783), AAV2 N587A capsid, AAV2 E548A capsid, AAV2 N708A capsid, AAV V708K capsid, goat AAV capsid, AAV1 / AAV2 capsid The AAV capsid is selected from the group consisting of a Mela capsid, a bovine AAV capsid, a murine AAV capsid, a rAAV2 / HBoV1 capsid, or an AAV capsid described in U.S. Pat. No. 8,283,151 or International Publication No. WO / 2003 / 042397. In some embodiments, the AAV capsid is an AAV2HBKO capsid described in WO2015168666. In some embodiments, the AAV capsid is an AAV9 capsid. In some embodiments, the AAV capsid is a PHP.B, PHP.eB, or Olig001 capsid. In some embodiments, the mutant capsid protein maintains the ability to form an AAV capsid. In some embodiments, the encapsidation protein is an AAV5 tyrosine mutant capsid protein. In further embodiments, the rAAV particle comprises capsid proteins of AAV serotypes from clades A-F. In some embodiments, the rAAV particles comprise a recombinant genome that includes an AAV1 capsid and an ITR of AAV2 and a nucleic acid encoding an RNAi of the present disclosure. In further embodiments, the rAAV particles are purified. The term "purified" as used herein encompasses preparations of rAAV particles that are devoid of at least some of the other elements that may be present when the rAAV particles are naturally present or initially prepared from. Thus, for example, isolated rAAV particles can be prepared using purification techniques to enrich them from a source mixture, such as a culture lysate or production culture supernatant. Enrichment can be measured in a variety of ways, such as by the proportion of DNase-resistant particles (DRP) or genome copies (gc) present in the solution, or infectivity, or enrichment can be measured with respect to a second potentially interfering substance present in the source mixture, such as a contaminant, such as a contaminant from the production culture, or a contaminant from the manufacturing process, such as a helper virus, a medium component, etc.
[0142] Numerous methods for producing adenoviral vector particles are known in the art. For example, in gutted adenoviral vectors, the genome of the adenoviral vector and the genome of a helper adenovirus are transfected into a packaging cell line (e.g., 293 cell line). In some embodiments, the helper adenoviral genome contains recombination sites adjacent to its packaging signal, and both genomes are transfected into a packaging cell line that expresses a recombinase (e.g., the Cre / loxP system can be used), so that the adenoviral vector of interest is packaged more efficiently than the helper adenovirus (see, e.g., Alba, R. et al. (2005) Gene Ther. 12 Suppl 1:S18-27). Adenoviral vectors can be recovered and purified using standard methods, such as those described herein.
[0143] Many methods for producing lentiviral vector particles are known in the art.For example, in third generation lentiviral vectors, a vector containing a lentiviral genome of interest with gag and pol genes is co-transfected with a vector containing a rev gene into a packaging cell line (e.g., 293 cell line). The lentiviral genome of interest also contains a chimeric LTR that promotes transcription in the absence of Tat (see Dull, T. et al. (1998) J. Virol. 72:8463-71). Lentiviral vectors can be collected and purified using the methods described herein (e.g., Segura MM et al. (2013) Expert Opin Biol Ther. 13(7):987-1011).
[0144] Numerous methods for producing HSV particles are known in the art. HSV vectors can be harvested and purified using standard methods, such as those described herein. For example, in a replication-defective HSV vector, the HSV genome of interest, lacking all of the immediate early (IE) genes, is transfected into a complementation cell line that provides genes necessary for virus production, e.g., ICP4, ICP27, and ICP0 (see, e.g., Samanie et al., 2003). (See Goins, LA et al. (1998) J. Virol. 72:3307-20). HSV vectors can be produced by the methods described (see, e.g., Goins, WF et al. (2014) The virus can be harvested and purified using the methods described in Methods in Herpes Simplex Virus (Herpes Simplex Virus Methods in Molecular Biology 1144:63-79).
[0145] Also provided herein is a pharmaceutical composition comprising recombinant virus particles comprising transgenes encoding the RNAi of the present disclosure and pharma- ceutical acceptable carriers.The pharmaceutical composition is suitable for any administration mode described herein.The pharmaceutical composition of recombinant virus particles comprising nucleic acid encoding the RNAi of the present disclosure can be introduced into the brain.For example, recombinant virus particles comprising nucleic acid encoding the RNAi of the present disclosure can be administered into the striatum.Any of the recombinant virus particles of the present disclosure can be used, including rAAV, adenovirus, lentivirus, and HSV particles.
[0146] In some embodiments, a pharmaceutical composition comprising a recombinant viral particle comprising a transgene encoding an RNAi of the present disclosure described herein and a pharma- ceutically acceptable carrier is suitable for administration to a human. Such carriers are well known in the art (see, e.g., Remington's Pharmaceutical Sciences, 15th Edition, pages 1035-1038 and 1570-1580). In some embodiments, a pharmaceutical composition comprising a rAAV as described herein and a pharma- ceutically acceptable carrier is suitable for injection into the mammalian brain (e.g., intrastriatal administration). In some embodiments, a pharmaceutical composition comprising a recombinant lentiviral particle as described herein and a pharma- ceutically acceptable carrier is suitable for injection into the mammalian brain (e.g., intrastriatal administration). In some embodiments, a pharmaceutical composition comprising a recombinant adenoviral particle as described herein and a pharma- ceutically acceptable carrier is suitable for injection into the mammalian brain (e.g., intrastriatal administration). In some embodiments, a pharmaceutical composition comprising a recombinant HSV particle as described herein and a pharma- ceutically acceptable carrier is suitable for injection into the mammalian brain (e.g., intrastriatal administration).
[0147] Such pharma-ceutically acceptable carriers may be sterile liquids, such as water and oils, such as oils of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, and the like. Saline solutions and aqueous dextrose, polyethylene glycol (PEG) and glycerol solutions may also be employed as liquid carriers, particularly for injectable solutions. The pharmaceutical compositions may further comprise additional components, such as preservatives, buffers, isotonicity agents, antioxidants and stabilizers, non-ionic wetting or clarifying agents, thickeners, and the like. The pharmaceutical compositions described herein may be packaged in single unit dosage forms or multi-dose dosage forms. The compositions are generally formulated as sterile, substantially isotonic solutions.
[0148] VII. Articles of Manufacture and Kits Kits or articles of manufacture for use in the methods described herein are also provided. In an embodiment, the kit comprises the composition described herein (e.g., the recombinant viral particles of the present disclosure, such as the rAAV particles that comprise the nucleic acid encoding the RNAi of the present disclosure) in a suitable package. Suitable packages for the compositions described herein (e.g., the intrastriatal compositions) are known in the art and include, for example, vials (e.g., sealed vials), containers, ampoules, bottles, jars, flexible packages (e.g., sealed Mylar or plastic bags), and the like. These articles of manufacture can be further sterilized and / or sealed.
[0149] The present invention also provides kits that include the compositions described herein, and may further include instructions on how to use the compositions, such as the uses described herein. The kit may further include other materials desirable from a commercial and user standpoint, such as other buffers, diluents, filters, needles, syringes, and inserts containing instructions for carrying out any of the methods described herein. For example, in some embodiments, the kit provides for the administration of at least 1×10 6 cells into the mammalian brain for a primate as described herein. 9 The kit includes one or more compositions of recombinant viral particles comprising a transgene encoding an RNAi of the present disclosure for delivery of a genome copy (e.g., intrastriatal administration), a pharma- ceutically acceptable carrier suitable for injection into the brain of a primate, and a package insert including buffers, diluents, filters, needles, syringes, and instructions for performing an injection into the brain of a primate (e.g., intrastriatal administration). In some embodiments, the kit includes instructions for treating a neurodegenerative synucleinopathic disease using the recombinant viral particles described herein. In some embodiments, the kit includes instructions for using the recombinant viral particles described herein according to any one of the methods described herein.
[0150] VIII. Exemplary Embodiments 1. An RNAi comprising a first strand and a second strand, wherein a) the first strand and the second strand form a duplex; b) the first strand comprises a guide region, the guide region comprising a nucleic acid having at least about 90% identity to the sequence 5'-UGCUCUUUGGUCUUCUCAGCC-3' (SEQ ID NO:24) or at least about 90% identity to the sequence 5'-UGGGCACAUUGGAACUGAGCA-3' (SEQ ID NO:8); and c) the second strand comprises a non-guide region.
[0151] 2. The RNAi of embodiment 1, wherein the guide region comprises the nucleic acid sequence 5'-UGCUCUUUGGUCUUCUCAGCC-3' (SEQ ID NO: 24) and the non-guide region comprises the sequence 5'-GGCUGAGAACCAAAGAGUA-3' (SEQ ID NO: 53).
[0152] 3. The RNAi of embodiment 1, wherein the first strand comprises a nucleic acid sequence having about 90% identity to SEQ ID NO: 24 or about 90% identity to SEQ ID NO: 53.
[0153] 4. The RNAi of embodiment 1, wherein the guide region comprises the nucleic acid sequence 5'-UGGGCACAUUGGAACUGAGCA-3' (SEQ ID NO: 8) and the non-guide region comprises the sequence 5'-UGCUCAGUCAAUGUGCCUA-3' (SEQ ID NO: 37).
[0154] 5. The RNAi of embodiment 1, wherein the second strand comprises a nucleic acid sequence having about 90% identity to SEQ ID NO:37 or about 90% identity to SEQ ID NO:37.
[0155] 6. The RNAi of any one of embodiments 1 to 5, wherein the first strand and the second strand are linked by an RNA linker capable of forming a loop structure.
[0156] 7. The RNAi of embodiment 6, wherein the RNA linker comprises 4 to 50 nucleotides.
[0157] 8. The RNAi of embodiment 6 or 7, wherein the loop structure comprises 4 to 20 nucleotides.
[0158] 9. The RNAi of any one of embodiments 6 to 8, wherein the RNAi comprises, from 5' to 3', a second strand, an RNA linker, and a first strand.
[0159] 10. The RNAi of any one of embodiments 6 to 8, wherein the RNAi comprises, from 5' to 3', a first strand, an RNA linker, and a second strand.
[0160] 11. The RNAi of embodiment 10, wherein the RNAi comprises the nucleic acid sequence of SEQ ID NO: 61 or SEQ ID NO: 63.
[0161] 12. The RNAi of embodiment 11, wherein the RNAi comprises a nucleotide sequence that is about 90% identical to the nucleotide sequence of SEQ ID NO:61 or SEQ ID NO:63.
[0162] 13. The RNAi of any one of embodiments 1 to 12, wherein the RNAi is a small inhibitory RNA (siRNA), a microRNA (miRNA), or a small hairpin RNA (shRNA).
[0163] 14. The RNAi of any one of embodiments 1 to 13, wherein the RNAi targets an RNA encoding a polypeptide associated with a neurodegenerative synucleinopathic disease.
[0164] 15. The RNAi of embodiment 14, wherein the polypeptide is alpha-synuclein (SNCA).
[0165] 16. The RNAi of embodiment 15, wherein the alpha synuclein is human alpha-synuclein.
[0166] 17. The RNAi of any one of embodiments 14-16, wherein the neurodegenerative synucleinopathy is Parkinson's disease (PD), multiple system atrophy (MSA), or dementia with Lewy bodies (DLB).
[0167] 18. An expression construct comprising a nucleic acid encoding the RNAi of any one of embodiments 1 to 17.
[0168] 19. The expression construct of embodiment 18, wherein the nucleic acid encoding the RNAi comprises a miRNA scaffold.
[0169] 20. The expression construct of embodiment 18 or 19, wherein the nucleic acid encoding the RNAi is operably linked to a promoter.
[0170] 21. The promoter is the cytomegalovirus (CMV) immediate early promoter, RSV 21. The expression construct of embodiment 20, wherein the promoter is selected from the group consisting of LTR, MoMLV LTR, phosphoglycerate kinase-1 (PGK) promoter, simian virus 40 (SV40) promoter, CK6 promoter, transthyretin promoter (TTR), TK promoter, tetracycline responsive promoter (TRE), HBV promoter, hAAT promoter, LSP promoter, chimeric liver specific promoter (LSP), E2F promoter, telomerase (hTERT) promoter; cytomegalovirus enhancer / chicken beta-actin / rabbit beta-globin promoter (CAG) promoter, elongation factor 1-alpha promoter (EF1-alpha) promoter, human beta-glucuronidase promoter, chicken beta-actin (CBA) promoter, retroviral Rous sarcoma virus (RSV) LTR promoter, dihydrofolate reductase promoter, and 13-actin promoter.
[0171] 22. The expression construct of any one of embodiments 18 to 21, further comprising an intron.
[0172] 23. The expression construct of embodiment 22, wherein the intron is a CBA intron or a hEF1 alpha intron.
[0173] 24. The expression construct of embodiment 22, wherein the intron is a chimeric intron.
[0174] 25. The expression construct of embodiment 22, wherein the expression vector is a self-complementary vector and the intron is a delta-chimeric intron.
[0175] 26. The expression construct of any one of embodiments 18 to 25, further comprising a polyadenylation signal.
[0176] 27. The expression construct of embodiment 26, wherein the polyadenylation signal is a bovine growth hormone polyadenylation signal, an SV40 polyadenylation signal, or an HSV TK polyadenylation signal.
[0177] 28. A vector comprising the expression construct of any one of embodiments 18 to 27.
[0178] 29. The vector of embodiment 28, which is a recombinant adeno-associated virus (rAAV) vector.
[0179] 30. The rAAV vector of embodiment 29, wherein the expression construct is flanked by one or more AAV inverted terminal repeat (ITR) sequences.
[0180] 31. The rAAV vector of embodiment 30, wherein the expression construct is flanked by two AAV ITRs.
[0181] 32. The rAAV vector of embodiment 30 or 31, wherein the ITRs of the AAV are an ITR of an AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAVrh8, AAVrh8R, AAV9, AAV10, AAVrh10, AAV11, AAV12, AAV2R471A, AAV DJ, caprine AAV, bovine AAV, or murine AAV serotype.
[0182] 33. The rAAV vector of any one of embodiments 30-32, wherein the ITRs of the AAV are ITRs of AAV2.
[0183] 34. The rAAV vector of any one of embodiments 30-33, further comprising a stuffer nucleic acid.
[0184] 35. The rAAV vector of embodiment 34, wherein the stuffer nucleic acid is positioned upstream or downstream of the nucleic acid encoding the RNAi.
[0185] 36. The rAAV vector of any one of embodiments 30-35, which is a self-complementary rAAV vector.
[0186] 37. The rAAV vector of embodiment 36, comprising a first nucleic acid sequence encoding an RNAi and a second nucleic acid sequence encoding a complement of the RNAi, wherein the first nucleic acid sequence is capable of intrastrand base pairing with the second nucleic acid sequence over most or all of its length.
[0187] 38. The rAAV vector of embodiment 37, wherein the first nucleic acid sequence and the second nucleic acid sequence are linked by a mutated AAV ITR, and the mutated AAV ITR comprises a deletion of the D region and a mutation of the terminal resolution sequence.
[0188] 39. A cell comprising the rAAV vector of any one of embodiments 29 to 38.
[0189] 40. Recombinant AAV particles comprising the rAAV vector of any one of embodiments 29 to 38. .
[0190] 41. The rAAV particle of embodiment 40, wherein the AAV viral particle comprises an AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAVrh8, AAVrh8R, AAV9, AAV10, AAVrhlO, AAV11, AAV12, AAV2R471A, AAV2 / 2-7m8, AAV DJ, AAV2 N587A, AAV2 E548A, AAV2 N708A, AAV V708K, AAV2-HBKO, AAVDJ8, AAVPHP.B, AAVPHP.eB, AAVBR1, AAVHSC15, AAVHSC17, caprine AAV, AAV1 / AAV2 chimera, bovine AAV, or murine AAV capsid rAAV2 / HBoV1 serotype capsid.
[0191] 42. The rAAV particle of embodiment 40 or 41, wherein the ITRs and the capsid of the rAAV viral particle are derived from the same AAV serotype.
[0192] 43. The rAAV particle of embodiment 40 or 41, wherein the ITRs and the capsid of the rAAV viral particle are derived from different AAV serotypes.
[0193] 44. The rAAV particle of embodiment 43, wherein the ITRs are derived from AAV2 and the capsid of the rAAV particle is derived from AAV1.
[0194] 45. A composition comprising the rAAV particles of any one of embodiments 40 to 44.
[0195] 46. The composition of embodiment 45, further comprising a pharma- ceutically acceptable carrier.
[0196] 47. A kit comprising the RNAi of any one of embodiments 1 to 17.
[0197] 48. A kit comprising the AAV particles of any one of embodiments 40 to 44.
[0198] 49. A kit comprising the composition of embodiment 45 or 46.
[0199] 50. The kit of any one of embodiments 47-49, further comprising instructions for use.
[0200] 51. A method for treating a neurodegenerative synucleinopathy in a mammal, comprising administering to the mammal an RNAi comprising a first strand comprising a first nucleic acid having at least about 90% identity to the sequence 5'-UGCUCUUUGGUCUUCUCAGCC-3' (SEQ ID NO:24) or a first strand comprising a first nucleic acid having at least about 90% identity to the sequence 5'-UGGGCACAUUGGAACUGAGCA-3' (SEQ ID NO:8) and a second strand comprising a second nucleic acid.
[0201] 52. The method of embodiment 51, wherein the second nucleic acid comprises a nucleic acid having at least about 90% identity to the sequence 5'-GGCUGAGAACCAAAGAGUA-3' (sequence number 53) or a nucleic acid having at least about 90% identity to the sequence 5'-E1 passenger-3' (sequence number 37).
[0202] 53. A method for treating a neurodegenerative synucleinopathy in a mammal, comprising administering to the mammal a first strand comprising a first nucleic acid having at least about 90% identity to the sequence 5'-UGCUCUUUGGUCUUCUCAGCC-3' (SEQ ID NO: 24) and a second strand comprising a second nucleic acid having at least about 90% identity to the sequence 5'-GGCUGAGAACCAAAGAGUA-3' (SEQ ID NO: 53), or a second strand comprising a second nucleic acid having at least about 90% identity to the sequence 5'-UGGGCA Administering an RNAi comprising a first strand comprising a first nucleic acid having at least about 90% identity to the sequence 5'-CAUUGGAACUGAGCA-3' (SEQ ID NO: 8) and a second strand comprising a second nucleic acid having at least about 90% identity to the sequence 5'-UGCUCAGUCAAUGUGCCUA-3' (SEQ ID NO: 37).
[0203] 54. A method for inhibiting expression of alpha-synuclein in a mammal having a neurodegenerative disease, comprising administering to the mammal an RNAi comprising a first strand comprising a first nucleic acid having at least about 90% identity to the sequence 5'-UGCUCUUUGGUCUUCUCAGCC-3' (SEQ ID NO:24) or a first strand comprising a nucleic acid having at least about 90% identity to the sequence 5'-UGGGCACAUUGGAACUGAGCA-3' (SEQ ID NO:8), and a second strand comprising a second nucleic acid.
[0204] 55. The method of embodiment 54, wherein the second nucleic acid comprises a nucleic acid having at least about 90% identity to the sequence 5'-GGCUGAGAACCAAAGAGUA-3' (sequence number 53) or a nucleic acid having at least about 90% identity to the sequence 5'-UGCUCAGUCAAUGUGCCUA-3' (sequence number 37).
[0205] 56. A method for inhibiting expression of alpha-synuclein in a mammal having a neurodegenerative disease, comprising administering to the mammal an RNAi comprising a first strand comprising a first nucleic acid having at least about 90% identity to the sequence 5'-UGCUCUUUGGUCUUCUCAGCC-3' (SEQ ID NO:24) and a second strand comprising a second nucleic acid having at least about 90% identity to the sequence 5'-GGCUGAGAACCAAAGAGUA-3' (SEQ ID NO:53), or a first strand comprising a first nucleic acid having at least about 90% identity to the sequence 5'-UGGGCACAUUGGAACUGAGCA-3' (SEQ ID NO:8) and a second strand comprising a second nucleic acid having at least about 90% identity to the sequence 5'-UGCUCAGUCAAUGUGCCUA-3' (SEQ ID NO:37).
[0206] 57. The method of any one of embodiments 51 to 56, wherein the first strand comprises a nucleic acid sequence having the sequence of SEQ ID NO: 24 or a nucleic acid having the sequence of SEQ ID NO: 8.
[0207] 58. The method of any one of embodiments 52, 53, 55, or 56, wherein the second strand comprises a nucleic acid having the sequence of SEQ ID NO: 53 or a nucleic acid having the sequence of SEQ ID NO: 37.
[0208] 59. The method of any one of embodiments 51-58, wherein the first strand and the second strand are linked by an RNA linker capable of forming a loop structure.
[0209] 60. The method of embodiment 59, wherein the RNA linker comprises 4 to 50 nucleotides.
[0210] 61. The method of embodiment 59 or 60, wherein the loop structure comprises 4 to 20 nucleotides.
[0211] 62. The method of any one of embodiments 59-61, wherein the RNAi comprises, from 5' to 3', a second strand, an RNA linker, and a first strand.
[0212] 63. The method of any one of embodiments 59-61, wherein the RNAi comprises, from 5' to 3', a first strand, an RNA linker, and a second strand.
[0213] 64. The method of embodiment 63, wherein the RNAi comprises a nucleic acid sequence of SEQ ID NO: 61 or SEQ ID NO: 63.
[0214] 65. The method of embodiment 64, wherein the RNAi comprises a nucleotide sequence that is about 90% identical to the nucleotide sequence of SEQ ID NO: 61 or SEQ ID NO: 63.
[0215] 66. The method of any one of embodiments 51 to 65, wherein the RNAi is encoded by an expression construct.
[0216] 67. The method of any one of embodiments 51-66, wherein the nucleic acid encoding the RNAi comprises an miRNA scaffold.
[0217] 68. The method of any one of embodiments 51-67, wherein the nucleic acid encoding the RNAi is operably linked to a promoter.
[0218] 69. The method of embodiment 68, wherein the promoter is capable of expressing RNAi in the mammalian brain.
[0219] 70. The promoter is the cytomegalovirus (CMV) immediate early promoter, RSV 70. The method of embodiment 69, wherein the promoter is selected from the group consisting of LTR, MoMLV LTR, phosphoglycerate kinase-1 (PGK) promoter, simian virus 40 (SV40) promoter, CK6 promoter, transthyretin promoter (TTR), TK promoter, tetracycline responsive promoter (TRE), HBV promoter, hAAT promoter, LSP promoter, chimeric liver specific promoter (LSP), E2F promoter, telomerase (hTERT) promoter; cytomegalovirus enhancer / chicken beta-actin / rabbit beta-globin (CAG) promoter, elongation factor 1-alpha promoter (EF1-alpha) promoter, and human beta-glucuronidase promoter.
[0220] 71. The method of any one of embodiments 68 to 70, wherein the promoter is a hybrid chicken beta-actin promoter (CBA) comprising a CMV enhancer and a chicken beta-actin promoter.
[0221] 72. The method of any one of embodiments 66 to 71, wherein the expression construct further comprises an intron.
[0222] 73. The method of embodiment 72, wherein the intron is a CBA intron.
[0223] 74. The method of embodiment 72, wherein the intron is a chimeric intron.
[0224] 75. The method of embodiment 74, wherein the expression construct is a self-complementary vector and the intron is a delta-chimeric intron.
[0225] 76. The method of any one of embodiments 66 to 75, wherein the nucleic acid further comprises a polyadenylation signal.
[0226] 77. The method of embodiment 76, wherein the polyadenylation signal is a bovine growth hormone polyadenylation signal.
[0227] 78. The method of any one of embodiments 66 to 77, wherein the expression construct is encoded by a vector.
[0228] 79. The method of embodiment 78, wherein the vector is a recombinant adeno-associated virus (rAAV) vector.
[0229] 80. The method of embodiment 79, wherein the expression construct is flanked by one or more AAV inverted terminal repeat (ITR) sequences.
[0230] 81. The method of embodiment 80, wherein the expression construct is flanked by two AAV ITRs.
[0231] 82. The method of embodiment 80 or 81, wherein the ITR of the AAV is an ITR of an AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAVrh8, AAVrh8R, AAV9, AAV10, AAVrh10, AAV11, AAV12, AAV2R471A, AAV DJ, caprine AAV, bovine AAV, or murine AAV serotype.
[0232] 83. The method of any one of embodiments 80-82, wherein the ITR of the AAV is an ITR of AAV2.
[0233] 84. The method of embodiment 83, wherein the rAAV vector comprises, from 5' to 3', an AAV2 ITR, a promoter, an intron, a nucleic acid encoding RNAi, a polyadenylation signal, and an AAV2 ITR.
[0234] 85. The method of embodiment 84, wherein the promoter is a CBA promoter.
[0235] 86. The method of embodiment 84, wherein the intron is a chimeric intron, a delta-chimeric intron or a truncated chimeric intron.
[0236] 87. The method of embodiment 86, wherein the chimeric intron is a CBA+ rabbit beta globulin intron.
[0237] 88. The method of any one of embodiments 84-87, wherein the polyadenylation signal is a bovine growth hormone polyadenylation signal.
[0238] 89. The method of embodiment 83, wherein the rAAV vector comprises, from 5' to 3', an AAV2 ITR, a CBA promoter, a chimeric intron, a nucleic acid encoding an RNAi, a bovine growth hormone polyadenylation signal, and an AAV2 ITR.
[0239] 90. The method of embodiment 89, wherein the vector further comprises a stuffer nucleic acid.
[0240] 91. The method of embodiment 90, wherein the stuffer nucleic acid comprises intron 1 of the human A1AT gene.
[0241] 92. The method of any one of embodiments 79 to 91, wherein the vector is a self-complementary vector.
[0242] 93. The method of embodiment 92, wherein the vector comprises a first nucleic acid sequence encoding an RNAi and a second nucleic acid sequence encoding a complement of the RNAi, and the first nucleic acid sequence is capable of intrastrand base pairing with the second nucleic acid sequence over most or all of its length.
[0243] 94. The first nucleic acid sequence and the second nucleic acid sequence are linked by a mutated AAV ITR, the mutated AAV ITR comprising a deletion of the D region and a terminal resolution sequence. 94. The method of embodiment 93, comprising a mutation.
[0244] 95. The method of any one of embodiments 79-94, wherein the vector is encapsidated in an rAAV particle.
[0245] 96. The method of embodiment 95, wherein the AAV viral particle comprises an AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAVrh8, AAVrh8R, AAV9, AAV10, AAVrh10, AAV11, AAV12, AAV2R471A, AAV2 / 2-7m8, AAV DJ, AAV2 N587A, AAV2 E548A, AAV2 N708A, AAV2 V708K, AAV2-HBKO, AAVDJ8, AAVPHP.B, AAVPHP.eB, AAVBR1, AAVHSC15, AAVHSC17, caprine AAV, AAV1 / AAV2 chimera, bovine AAV, murine AAV, or rAAV2 / HBoV1 serotype capsid.
[0246] 97. The method of embodiment 95 or 96, wherein the ITRs and the capsid of the rAAV viral particle are derived from the same AAV serotype.
[0247] 98. The method of embodiment 95 or 96, wherein the ITRs and the capsid of the rAAV viral particle are derived from different AAV serotypes.
[0248] 99. The method of any one of embodiments 95 to 98, wherein the rAAV viral particle comprises an AAV2 capsid.
[0249] 100. The method of embodiment 99, wherein the rAAV viral particle comprises an AAV1 capsid and the vector comprises the ITRs of AAV2.
[0250] 101. The method of any one of embodiments 51 to 100, wherein the rAAV particles of any one of embodiments 95 to 100 are in the form of a composition.
[0251] 102. The method of embodiment 101, wherein the composition further comprises a pharma- ceutically acceptable carrier. EXAMPLES
[0252] The present disclosure will be better understood by referring to the following examples.However, they should not be interpreted as limiting the scope of the present disclosure.It is understood that the examples and embodiments described herein are merely for illustrative purposes, and various modifications or changes in view thereof are expected to be suggested to those skilled in the art, and are encompassed within the spirit and intent of the present application and the scope of the appended claims.
[0253] Example 1: shmiRNA reduces human SNCA target in vitro. To demonstrate reduction of SNCA expression in vitro, HEK293T cells were transfected with plasmids encoding candidate RNAi sequences and human SNCA cDNA A (NM_000345.3) under the control of the cytomegalovirus enhancer and hEF1a promoter / intron, followed by a Tbgh polyA sequence. SNCA cDNA and miRNA plasmids were co-transfected.
[0254] method siRNAs and plasmids RNAi sequences were designed in-house to have maximal homology to human / macaque / mouse SNCA while balancing this with low off-targeting potential. Conventional siRNAs were synthesized by Sigma. Off-targets in the human transcriptome were predicted using the siSPOTR algorithm (available on the World Wide Web at https: / / sispotr.icts.uiowa.edu / sispotr / tools.html).
[0255] A plasmid expressing an RNAi sequence targeting SNCA was embedded within a mouse mir155 scaffold driven by a cytomegalovirus enhancer and hEF1a promoter / intron. The RNAi sequence can be found in Table 1.
[0256] In vitro cell culture and transfection HEK293T cells were grown to approximately 70-90% confluency in DMEM + 10% FBS + pen / strep. Cells were transfected with Lipfectamine 2000 (as plasmid in miRNA format) or RNAiMAX (as siRNA format). Three days after transfection, cells were rinsed with phosphate-buffered saline and whole cell extracts were prepared by cell lysis in reducing Laemmli buffer and boiled for 5 min before storing at -20°C.
[0257] Western blotting and densitometry Cell lysates were run on 4-12% SDS-PAGE (Bio-Rad TGX™). Proteins were transferred to nitrocellulose (Bio-Rad Transblot™), blocked in 5% nonfat milk, and incubated with primary antibodies overnight at 4°C. Primary antibodies were washed out and incubated with HRP-tagged secondary antibodies, HRP activity was detected using Femto ECL substrate (Bio-Rad), and imaged on a Bio-Rad GelDoc™ imager. Bands were quantified using ImageJ software (NIH). Alpha-synuclein protein levels were normalized to GAPDH or beta-tubulin to control for protein loading. Antibodies used: alpha-synuclein (BD 610787), GAPDH (Sigma G8795), Tubulin (BioLegend MMS-435P-100). HRP-goat anti-mouse or rabbit (CST 7076).
[0258] result As shown in Figure 2, shmiRNAs reduced human SNCA protein levels in vitro, with 19 / 27 sequences showing a greater than 50% reduction in protein levels.
[0259] Example 2: shmiRNA reduces mouse SNCA target in vitro. In this experiment, a method similar to that of Example 1 was used, except that HEK293T cells were transfected with plasmids encoding the indicated RNAi sequences and mouse SNCA cDNA.
[0260] result As shown in FIG. 3, the indicated miRNAs reduced mouse SNCA protein levels in vitro, with 14 / 27 sequences showing greater than 50% reduction in protein levels.
[0261] Example 3: siRNA reduces human and mouse SNCA targets in vitro. Additional experiments using siRNA formats were performed for A1, A2, B1, B2, C1, C2, D1, D2, E1 and E2 to provide additional data on target reduction, which indicates that these have complete, or significant, comparative effects on SNCA in rats, allowing flexibility in selecting future animal models of neurodegeneration requiring SNCA reduction in rats. This is because it was designed to have an additional configuration with the same gender.
[0262] method In vitro cell culture and transfection HEK293T cells were grown to approximately 70-90% confluency in DMEM + 10% FBS + pen / step. Cells were transfected with Lipfectamine 2000 (as plasmid in miRNA format) or RNAiMAX (as siRNA format). Three days after transfection, cells were rinsed with phosphate-buffered saline and whole cell extracts were prepared by cell lysis in reducing Laemmli buffer and boiled for 5 min before storage at -20°C.
[0263] Western blotting and densitometry Cell lysates were run on 4-12% SDS-PAGE (Bio-Rad TGX™). Proteins were transferred to nitrocellulose (Bio-Rad Transblot™), blocked in 5% nonfat milk, and incubated with primary antibodies overnight at 4C. Primary antibodies were washed out and incubated with HRP-tagged secondary antibodies, HRP activity was detected using Femto ECL substrate (Bio-Rad), and imaged on a Bio-Rad GelDoc™ imager. Bands were quantified using ImageJ software (NIH). Alpha-synuclein protein levels were normalized to GAPDH or beta-tubulin to control for protein loading. Antibodies used: alpha-synuclein (BD 610787), GAPDH (Sigma G8795), Tubulin (BioLegend MMS-435P-100). HRP-goat anti-mouse or rabbit (CST 7076).
[0264] result As shown in Figures 4A-4D, the indicated siRNAs reduced human and mouse SNCA levels in vitro, as expected based on their performance in the miRNA format.
[0265] Example 4: Toxicity and neuroprotective properties of demonstrated RNAi. Lund human midbrain (LUHMES) cells differentiated into mature dopamine-like neurons ( 10 ) were used to evaluate the toxicity and neuroprotective properties of candidate shmiRNAs.
[0266] method In vitro cell culture and transfection LUHMES cells (ATCC CRL-2927) were grown and differentiated as described in (10) with some modifications to allow electroporation of plasmid DNA. Briefly, LUHMES cells were subcultured in growth medium (10) on flasks coated with poly-L-ornithine and fibronectin. Differentiation of dopaminergic cells was initiated with the addition of differentiation medium (10). After 2 days, cells were dissociated, electroporated with the desired DNA (LONZA 4D Nucleofector™ X system according to the manufacturer's instructions), and replated in 96-well plates in recovery medium to minimize electroporation toxicity. Four hours after transfection, medium was returned to differentiation medium. For specific experiments, cells were treated and harvested on the indicated days after transfection.
[0267] In vitro neuroprotection assay LUHMES cells prepared as described above were treated with the indicated concentrations of rotenone on day 6 of differentiation (day 4 after transfection). 48 hours after treatment with rotenone, cells were incubated with Cell Titer Blue® assay according to the manufacturer's instructions (Promega). Cell viability was measured using a sieve. Reactive oxygen species (ROS) generation was measured by DCFDA kit (Abcam) 24 hours after treatment. Values were normalized to untreated control transfected cells.
[0268] statistical analysis Data from experiments on cell viability were compiled and the % of SNCA mRNA knockdown was ranked against the % of neuroprotection against rotenone-induced toxicity using the D1 and E1 sequences. As calculated using Graphpad Prism® (v6), the percent SNCA knockdown correlated significantly with the degree of neuroprotection.
[0269] result As shown in Figures 5A and 5B, SNCA knockdown is not toxic in itself, but significantly prevents cell death (Figure 5A) and reduces rotenone-dependent ROS generation (Figure 5B). The control, D1 and E1 sequences did not alter cell viability in themselves. Rotenone treatment of control transfected cells resulted in approximately 75% cell death, whereas transfection with the SNCA knockdown vector provided significant protection from this toxicity.
[0270] Data from experiments on cell viability were compiled and the % of SNCA mRNA knockdown using the D1 and E1 sequences was ranked against the percent of neuroprotection against rotenone-induced toxicity, as shown in Figure 6. The degree of SNCA knockdown significantly positively correlated with the degree of neuroprotection, demonstrating that reduction of SNCA mRNA using the D1 and E1 sequences is an effective neuroprotective strategy.
[0271] Example 5: Targeted knockdown in vivo with D1 and E1 vectors To determine in vivo knockdown of SNCA, AAV vectors encoding D1, E1 or control RNAi sequences were injected into the SNc of wild-type mice. SNc tissues were harvested one month after injection. RNA was isolated and SNCA mRNA levels were quantified by Taqman qPCR. Relative transcript levels were normalized to GAPDH.
[0272] method Viral Vectors To produce rAAV virus for in vivo testing, the mir155 cassette was cloned into the ITR plasmid of AAV2, which contains a 1.6 kb CAG promoter for AAV virus production, using a modified AAV2HBKO capsid (WO 2015168666 A2). All viral vectors were produced by triple transfection method in 293 cells and purified as described in (11). Titers were determined by qPCR and expressed as genome copies (GC) / mL or as total vector genome (vg).
[0273] animal Male C57BL / 6J mice (10-12 weeks old) were purchased from Charles River Laboratories, France. Animals were housed in groups of four in each cage with free access to food and water, controlled temperature, humidity, and a 12:12 h light / dark cycle.
[0274] Stereotactic injection Ketamine (100 mg / kg; Imalgene®; Merial, Fra Mice were deeply anesthetized by intraperitoneal injection of a mixture (volume 10 mL / Kg) of 100 mg / Kg ...
[0275] A small hole was drilled in the skull on the injection coordinates. A 33-gauge cannula (OD 0.254 mm; Phymep), connected to a 25 μL syringe with flexible plastic tubing and then to a microperfusion pump, was inserted unilaterally into the left substantia nigra pars compacta (SNpc) at the following coordinates: AP = -2.92 mm from the anterior midline; ML = 1.25 mm; DV: -4.5 mm from the dura, according to the mouse atlas of Paxinos and Watson (2008). After randomization, mice (n = 10 / group) were injected with AAV. Injections were performed at a flow rate of 0.2 μL / min, and a final volume of 1 μL was injected.
[0276] After the final injection, the cannula was kept in the SNpc for another 5 min to avoid reflux. The cannula was then slowly removed from the mouse brain and the scalp was sutured closed. The mice were monitored daily and after surgery received a subcutaneous injection of carprofen (5 mg / kg sc; volume 5 ml / kg; Rimadyl®, Zoetis) and approximately 200 μL of sterile saline was injected intraperitoneally to prevent dehydration. The animals were then placed in a MediHeat® Warming Cabinet until fully awake. One month after injection, the animals were anesthetized with isoflurane 4% and the brains were processed for immunohistochemistry and biochemistry analysis. All experiments were performed blinded.
[0277] statistical analysis Statistics were performed using Prism software (version 6, Graphpad®) using one-way ANOVA with multiple comparisons (Dunnett's test) where appropriate.
[0278] result As shown in Figure 7 , the D1 and E1 vectors showed 55% and 66% knockdown of SNCA mRNA, respectively, relative to control RNAi, demonstrating significant target mRNA knockdown in vivo in the target construct using AAV-mediated delivery of SNCA-targeting miRNA.
[0279] As shown in Figure 8, the SNCA antisense probe clearly shows targeted reduction at three different anatomical levels from rostral to caudal to the contralateral hemisphere. The control RNAi virus showed no reduction in SNCA mRNA relative to the uninjected hemisphere, demonstrating specificity of action. As shown in Figure 9, the alpha-synuclein protein signal in the VTA had to be saturated to observe somatic synuclein expression, precluding any determination of SNCA reduction in that brain region.
[0280] Example 6: AAV-D1 vector reduces mouse SNCA mRNA by SNc immunohistochemistry. Mice were unilaterally injected with 1e9 GC of control or D1 AAV vector as described in Example 5. One month later, tissues were harvested and coronal sections were processed for immunohistochemistry (IHC) to assess alpha-synuclein protein levels in the substantia nigra pars compacta.
[0281] Additional methods Immunohistochemistry and ISH Brains were immersion fixed in 4% formaldehyde for at least 2 days at 4°C, cryopreserved in 30% sucrose solution, and then frozen. Frozen brains were cut into serial coronal sections along the entire anterior-posterior axis of the substantia nigra (sn). Sections were placed in PBS-0.4% sodium azide and stored at 4°C.
[0282] Using a series of randomly selected 20 μm thick free-floating sections, immunolabeling was performed with a mouse monoclonal primary antibody against α-syn (mouse monoclonal, 1:2000, clone 42, BD transductions laboratories), which is capable of detecting endogenous levels of mouse α-Syn protein, which is mainly localized not only at synaptic membranes but also within da neuronal cell bodies in the ventral tegmental area (VTA) and SN.
[0283] Sections were rinsed three times in 0.1 m PBS-0.15% Triton, 0.2% gelatin from bovine skin (Sigma, G9391) solution and pretreated for 30 min in blocking buffer (i.e., 0.1 m PBS-10% albumin from bovine serum, Sigma, A8022). They were then incubated overnight with primary antibody solution in 0.1 m PBS at room temperature. After rinsing in 0.1 m PBS-0.15% Triton, 0.2% gelatin, a fluorescent dye-conjugated antibody (goat anti-mouse 647, Abcam 150119) was used as the secondary antibody (1:400 in 0.1 m PBS, 90 min incubation at room temperature in the dark). Sections were rinsed twice in 0.1 m PBS-0.2% gelatin solution and once in 0.1 m PBS and fixed (flex slide, Dako). Sections were coverslipped using prolong gold antifade reagent (Invitrogen p36931).
[0284] Qualitative image analysis of fluorescent immunolabeling was performed with a slide scanner system (Olympus DotSlide system equipped with a BX61 microscope with fluorescence capabilities).
[0285] result As shown in Figure 9, SNCA protein in the soma is clearly reduced by D1 compared to the contralateral SNc of the same animal or control-injected animals. ISH images from adjacent brain sections (lower panel, processed according to Example 5) showed a corresponding reduction in SNCA mRNA by the D1 RNAi vector, but not the control vector. These data demonstrate that AAV delivery of miRNA-targeted SNCA shows durable mRNA knockdown in the desired brain region.
[0286] Example 7: Targeted knockdown in vivo by E1 in the vector AAVrh.10 To determine in vivo knockdown of SNCA and demonstrate that SNCA knockdown is AAV serotype independent, AAV.rh10 vectors encoding E1 or control RNAi sequences were injected into the SNc of wild-type mice. Mice were injected unilaterally with 10e9 GC of control or AAV.rh10 E1 vectors as previously described. SNc tissues were harvested 1 month after injection. SNCA mRNA expression was quantified by in situ hybridization and SNCA protein was detected by immunohistochemistry.
[0287] method Viral Vectors To generate rAAV viruses for in vivo studies, the capsid of the rh.10 serotype of AAV (Gao, GP et al., 2002, Proc. Natl. Acad. Sci. USA 99: 11854-11859) was used to generate rAAV viruses. The mir155 cassette was cloned into the ITR plasmid of AAV2, which contains a 1.6 kb CAG promoter for viral production. All viral vectors were produced by triple transfection in 293 cells and purified as described (11). Titers were determined by qPCR and expressed as genome copies (GC) / mL or as total vector genome (vg).
[0288] animal Male C57BL / 6J mice (10-12 weeks old) were purchased from Charles River Laboratories, France. Animals were housed in groups of four in each cage with free access to food and water, controlled temperature, humidity, and a 12:12 h light / dark cycle.
[0289] Stereotactic injection Mice were deeply anesthetized by intraperitoneal injection of a mixture (volume 10 mL / Kg) of ketamine (100 mg / kg; Imalgene®; Merial, France) and xylazine (10 mg / Kg; Rompun®; Bayer, France). Before placing the animals in a stereotaxic frame (Kopf Instruments, USA), the mouse scalp was shaved and disinfected with Vetidine (Vetoquinol®, France), the local anaesthetic bupivacaine (2 mg / kg in a volume of 5 ml / kg; Aguettant, France) was injected subcutaneously into the skin of the skull, and Emla (Lidocaine, Astrazeneca) was applied to the ears. During the surgery, the eyes were protected from light by Vitamin A Dulcis and the body temperature was kept constant at 37°C by an electric blanket.
[0290] A small hole was drilled in the skull at the injection coordinates. Flexible plastic tubing (Tygon 0.254 * 0.762, ref. AAD04091) using a 25 μL syringe (Exmire, ref. MS *A 33-gauge cannula (OD 0.254 mm; Phymep) connected to a 3-mm suction tube (GF25) and then to a microperfusion pump (CMA 4004) was inserted unilaterally into the left substantia nigra pars compacta (SNpc) at the following coordinates: AP = -2.92 mm from the anterior midline; ML = 1.25 mm; DV: -4.5 mm from the dura, according to the mouse atlas of Paxinos and Watson (2008). After randomization, mice (n = 10 / group) were injected with AAV. Injections were performed at a flow rate of 0.2 μL / min, and a final volume of 1 μL was injected. After the final injection, the cannula was maintained in the SNpc for an additional 5 min to avoid reflux. The cannula was then slowly removed from the mouse brain and the scalp was sutured closed. Mice were monitored daily and after surgery received a subcutaneous injection of carprofen (5 mg / kg sc; volume 5 ml / kg; Rimadyl, Zoetis) and approximately 200 μL of sterile saline was injected intraperitoneally to prevent dehydration. Animals were then placed in a MediHeat® Warming Cabinet (Peco services) until fully awake. One month after injection, animals were anesthetized with isoflurane 4% and brains were processed for immunohistochemistry and biochemistry analysis. All experiments were performed blinded.
[0291] Immunohistochemistry and ISH Brains were immersion fixed in 4% formaldehyde for at least 2 days at 4°C, cryopreserved in 30% sucrose solution, and then frozen. Frozen brains were cut into serial coronal sections along the entire anterior-posterior axis of the substantia nigra (SN). Sections were placed in PBS-4% sodium azide and stored at 4°C.
[0292] Using a series of randomly selected 20 μm thick free-floating sections, immunolabeling was performed with a mouse monoclonal primary antibody against α-syn (mouse monoclonal, 1:2000, clone 42, BD Transductions laboratories). This antibody binds not only to synaptic membranes but also to DA nerves in the ventral tegmental area (VTA) and SN. Endogenous levels of mouse α-Syn protein, which is also primarily localized within the cell body, can be detected.
[0293] For enzymatic development of IHC for α-syn, after incubation in the primary antibody solution, sections were incubated with biotinylated mouse IgG (BA 9200 Vector Lot S0913, 1 / 400 dilution) for 90 min, then with peroxidase-linked avidin complex (Vectastain® ABC Kit Elite, Vector PK 6100, 1 / 200 dilution) for 30 min at room temperature. Sections were briefly incubated in peroxidase substrate solution (containing 0.003% hydrogen peroxide, 0.05% diaminobenzidine tetrahydrochloride in 0.1 M PBS) and finally rinsed in 0.9% NaCl solution. Finally, sections were fixed on slides, dried at room temperature, dehydrated and coverslipped using Eukitt.
[0294] For ISH studies of α-syn, a fully automated RNAscope assay (improving the signal-to-noise ratio of RNA ISH by amplifying the target-specific signal but not the background noise from non-specific hybridization) on 20 μm-thick cryostat sections fixed on slides was performed using the Roche Ventana Medical Systems DISCOVERY XT (VS) automate. (RNAscope® 2.5 VS antisense probe- Hs-SNCA (cat. no. 313289) and control sense probe (cat. no. 511079) were hybridized for 2 hours at 43°C, followed by RNAscope amplification and detection of Red chromogen using VS detection reagents. RNAscope probes are designed as described herein. Stained slides were scanned on a VS120 Olympus system using a 40X objective.
[0295] statistical analysis Statistics were performed using Prism software (version 6, Graphpad®) using one-way ANOVA with multiple comparisons (Dunnett's test) where appropriate.
[0296] result As shown in Figure 10, SNCA protein in the soma is clearly reduced by construct E1 in AAVrh.10 capsid (upper panel) compared to animals injected with the contralateral SNc or control of the same animals. ISH images from adjacent brain sections (lower panel) show corresponding targeted reduction of SNCA mRNA by AAVrh.10 but not in the contralateral hemisphere. Control RNAi virus showed no reduction of SNCA mRNA relative to uninjected hemisphere, demonstrating specificity of action. It is demonstrated herein that the efficiency of knockdown of SNCA by E1 is independent of the serotype of capsid, at least after intranigral injection of the vector.
[0297] Example 8: Potential off-targets of D1 and E1 Lund Human Mesencephalic (LUHMES) cells were cultured and differentiated, then transfected with plasmids expressing D1, E1, or CTL3 (control) microRNAs in an optimized mouse endogenous miR-155 scaffold (ThermoFisher). Total RNA was isolated from cells using the miRNeasy® kit (Qiagen), and next-generation sequencing libraries were prepared using the TruSeq stranded Total RNA Library Prep kit (Illumina), followed by sequencing on an Illumina HiSeq instrument (Genewiz, Plainfield NJ).
[0298] Sequencing analysis was performed at Sanofi's Genomics group using Array Studio (Omicsoft, A Qiagen Company). Low-quality reads were removed, and the remaining reads were mapped to the human genome, followed by one-way ANOVA to determine significantly differentially expressed genes (DEGs) among the treatment groups. Genes downregulated by both D1 and E1 relative to CTL3 with a p-value of less than 0.05 were considered to be the result of knocking down alpha-synuclein, and the remaining genes downregulated by at least 1.2-fold with a p-value of less than 0.05 were classified as possible off-targets. Alpha-synuclein was knocked down by 22% by D1 and 30% by E1, with the individual data points shown below in Figure 11. The possible off-targets for D1 and E1 are listed in Tables 2 and 3. TNFRSF6B in the D1 list was a predicted tumor suppressor only in the NCKU database, and none of the genes in the E1 list were predicted to be tumor suppressors in either the NCKU or TSGene databases. Both the D1 and E1 lists of possible off-targets overlapped with predicted targets for D1 and E1 microRNAs identified using the miRanda, siSPOTR, and TargetRank (data not included) algorithms.
[0299] [Table 2]
[0300] [Table 3]
[0301] References 1. S. T. Baek et al., Off-target effect of doublecortin family shRNA on neuronal migration associated with endogenous microRNA dysregulation. Neuron 82, 1255-1262 (2014). 2. W. Dauer et al., Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP. Proceedings of the National Academy of Sciences of the United States of America 99, 14524-14529 (2002). 3. R. E. Drolet, B. Behrouz, K. J. Lookingland, J. L. Goudreau, Mice lacking alpha-synuclein have an attenuated loss of striatal dopamine following prolonged chronic MPTP administration. Neurotoxicology25, 761-769 (2004). 4. D. Alvarez-Fischer et al., Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and alpha-synuclein-deleted mice. Experimental neurology 210, 182-193 (2008). 5. P. Klivenyi et al., Mice lacking alpha-synuclein are resistant to mitochondrial toxins. Neurobiology of disease 21, 541-548 (2006). 6. S. Mittal et al., beta2-Adrenoreceptor is a regulator of the alpha-synuclein gene driving risk of Parkinson's disease. Science 357, 891-898 (2017). 7. H. Javed et al., Development of Nonviral Vectors Targeting the Brain as a Therapeutic Approach For Parkinson's Disease and Other Brain Disorders. Molecular therapy : the journal of the American Society of Gene Therapy 24, 746-758 (2016). 8. K. Ubhi et al., Alpha-synuclein deficient mice are resistant to toxin-induced multiple system atrophy. Neuroreport 21, 457-462 (2010). 9. Y. Lim et al., alpha-Syn suppression reverses synaptic and memory defects in a mouse model of dementia with Lewy bodies. The Journal of neuroscience : the official journal of the Society for Neuroscience 31, 10076-10087 (2011). 10. S. Schildknecht et al., Generation of genetically-modified human differentiated cells for toxicological tests and the study of neurodegenerative diseases. Altex30, 427-444 (2013). 11. X. Xiao, J. Li, RJ Samulski, Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. Journal of virology 72, 2224-2232 (1998).
[0302] array All polypeptide sequences are represented from N-terminus to C-terminus unless otherwise specified. All nucleic acid sequences are represented from 5' to 3' unless otherwise specified.
[0303] D1-loop-passenger-RNA UGCUCUUUGGUCUUCUCAGCCGUUUUGGCCACUGACUGACGGCUGAGAACCAAAGAGUA (SEQ ID NO: 61)
[0304] D1-Loop-Passenger-DNA TGCTCTTTGGTCTTCTCAGCCGTTTTGGCCACTGACTGACGGCTGAGAACCAAAGAGTA (SEQ ID NO: 62)
[0305] E1-loop-passenger-RNA UGGGCACAUUGGAACUGAGCAGUUUUGGCCACUGACUGACUGCUCAGUCAAUGUGCCUA (SEQ ID NO: 63)
[0306] E1-loop-passenger-DNA TGGGCACATTGGAACTGAGCAGTTTTGGCCACTGACTGACTGCTCAGTCAATGTGCCTA (SEQ ID NO: 64)
[0307] Vector genome sequence of D1
[0308] A1AT stuffer nucleic acid ATTGTCTGAGTAGGTGTCATTCTATTCTGGGGGGTGGGGTGGGGCAGGACAGCAAGGGGGAGGATTGGGAAGACAATAGCAGGCATGCTGGGGAGCTAGAGTCGACCGGACCGGTGGAAGTCCTCTTCCTCGGTGTCCTTGACTTCAAAGGGTCTCTCCCATTTGCCTGGAGAGAGGGGAAGGTGGGCATCACCAGGGGTGAGTGAAGGTTTGGAAGAGTGTAGCAGAATAAGAAACCATGAGTCCCCTCCCTGAGAAGCCCTGAGCCCCCTTGACGACA CACATCCCTCGAGGCTCAGCTTCATCATCTGTAAAAGGTGCTGAAACTGACCATCCAAGCTGCCGAAAAAGATTGTGTGGGGATAATTCAAAACTAGAGGAAGATGCAGAATTTCTACATCGTGGCGATGTCAGGCTAAGAGATGCCATCGTGGCTGTGCATTTTTATTGGAATCATATGTTTATTTGAGGGTGTCTTGGATATTACAAATAAAATGTTGGAGCATCAGGCATATTTGGTACCTTCTGTCTAAGGCTCCCTGCCCCTTGTTAATTGGCAGCTCAGTTATTCATCCAGGGCAAACATTCTGCTTACTATTCCTGAGAGCTTTCCTCATCCTCTAGATTGGCAGGGGAAATGCAGATGCCTGAGCAGCCTCCCCTCTGCCATACCAACAGAGCTTCACCATCGAGGCATGCAGAGTGGACAGGGGCCTCAGGGACCCCTGATCCCAGCTTTCTCATTGGACAGAAGGAGGAGACTGGGGCTGGAGAGGGACCTGGGCCCCCACTAAGGCCACAGCAGAGCCAGGACTTTAGCTGTGCTGACTGCAGCCTGGCTTGCCTCCACTGCCCTCCTTTGCCTCAAGAGCAAGGGAGCCTCAGAGTGGAGGAAGCAGCCCCTGGCCTTGCCTCCCACCTCCCCTCCCCTATGCTGTTTTCCTGGGACAGTGGGAGCTGGCTTAGAATGCCCTGGGGCCCCCAGGACCCTGGCATTTTAACCCCTCAGGGGCAGGAAGGCAGCCTGAGATACAGAAGAGTCCATCACCTGCTGTATGCCACACACCATCCCCACAGTCGACATTTAAATT(SEQ ID NO: 66)
Claims
1. An RNAi comprising a first strand and a second strand, a) said first strand and said second strand form a duplex; b) the first strand comprises a guide region, the guide region comprising a nucleic acid having at least about 90% identity to the sequence 5'-UGCUCUUUGGUCUUCUCAGCC-3' (SEQ ID NO:24) or at least about 90% identity to the sequence 5'-UGGGCACAUUGGAACUGAGCA-3' (SEQ ID NO:8); and c) the RNAi, wherein the second strand comprises a non-guide region.
2. The RNAi of claim 1, wherein the guide region comprises the nucleic acid sequence 5'-UGCUCUUUGGUCUUCUCAGCC-3' (SEQ ID NO: 24) and the non-guide region comprises the sequence 5'-GGCUGAGAACCAAAGAGUA-3' (SEQ ID NO: 53).
3. The RNAi of claim 1, wherein the first strand comprises a nucleic acid sequence having about 90% identity to SEQ ID NO:24 or about 90% identity to SEQ ID NO:
53.
4. The RNAi of claim 1, wherein the guide region comprises the nucleic acid sequence 5'-UGGGCACAUUGGAACUGAGCA-3' (SEQ ID NO: 8) and the non-guide region comprises the sequence 5'-UGCUCAGUCAAUGUGCCUA-3' (SEQ ID NO: 37).
5. The RNAi of claim 1, wherein the second strand comprises a nucleic acid sequence having about 90% identity to SEQ ID NO:37 or about 90% identity to SEQ ID NO:
37.
6. The RNAi according to any one of claims 1 to 5, wherein the first strand and the second strand are linked by an RNA linker capable of forming a loop structure.
7. The RNAi of claim 6, wherein the RNA linker comprises 4 to 50 nucleotides.
8. The RNAi of claim 6 or 7, wherein the loop structure comprises 4 to 20 nucleotides.
9. The RNAi according to any one of claims 6 to 8, wherein the RNAi comprises, from 5' to 3', a second strand, an RNA linker, and a first strand.
10. The RNAi according to any one of claims 6 to 8, wherein the RNAi comprises, from 5' to 3', a first strand, an RNA linker, and a second strand.
11. The RNAi of claim 10, wherein the RNAi comprises a nucleic acid sequence of SEQ ID NO:61 or SEQ ID NO:
63.
12. The RNAi of claim 11, wherein the RNAi comprises a nucleotide sequence that is about 90% identical to the nucleotide sequence of SEQ ID NO:61 or SEQ ID NO:
63.
13. The RNAi of any one of claims 1 to 12, wherein the RNAi is a small inhibitory RNA (siRNA), a microRNA (miRNA), or a small hairpin RNA (shRNA).
14. The RNAi of any one of claims 1 to 13, wherein the RNAi targets an RNA encoding a polypeptide associated with a neurodegenerative synucleinopathic disease.
15. The method of claim 14, wherein the polypeptide is alpha-synuclein (SNCA).
16. The method of claim 15, wherein the alpha synuclein is human alpha-synuclein.
17. The RNAi according to any one of claims 14 to 16, wherein the neurodegenerative synucleinopathy is Parkinson's disease (PD), multiple system atrophy (MSA), or dementia with Lewy bodies (DLB).
18. An expression construct comprising a nucleic acid encoding the RNAi of any one of claims 1 to 17.
19. The expression construct of claim 18 , wherein the nucleic acid encoding the RNAi comprises an miRNA scaffold.
20. 20. The expression construct of claim 18 or 19, wherein the nucleic acid encoding the RNAi is operably linked to a promoter.
21. The promoters are the cytomegalovirus (CMV) immediate early promoter, the RSV LTR, and the MoMLV 21. The expression construct of claim 20, selected from LTR, phosphoglycerate kinase-1 (PGK) promoter, simian virus 40 (SV40) promoter, CK6 promoter, transthyretin promoter (TTR), TK promoter, tetracycline responsive promoter (TRE), HBV promoter, hAAT promoter, LSP promoter, chimeric liver specific promoter (LSP), E2F promoter, telomerase (hTERT) promoter; cytomegalovirus enhancer / chicken beta-actin / rabbit beta-globin promoter (CAG) promoter, elongation factor 1-alpha promoter (EF1-alpha) promoter, human beta-glucuronidase promoter, chicken beta-actin (CBA) promoter, retroviral Rous sarcoma virus (RSV) LTR promoter, dihydrofolate reductase promoter, and 13-actin promoter.
22. 22. The expression construct of any one of claims 18 to 21, further comprising an intron.
23. 23. The expression construct of claim 22, wherein the intron is a CBA intron or a hEF1 alpha intron.
24. 23. The expression construct of claim 22, wherein the intron is a chimeric intron.
25. 23. The expression construct of claim 22, wherein the expression vector is a self-complementary vector and the intron is a delta-chimeric intron.
26. 26. The expression construct of any one of claims 18 to 25, further comprising a polyadenylation signal.
27. 27. The expression construct of claim 26, wherein the polyadenylation signal is a bovine growth hormone polyadenylation signal, an SV40 polyadenylation signal, or an HSV TK polyadenylation signal.
28. A vector comprising an expression construct according to any one of claims 18 to 27.
29. 29. The vector of claim 28, which is a recombinant adeno-associated virus (rAAV) vector.
30. 30. The rAAV vector of claim 29, wherein the expression construct is flanked by one or more AAV inverted terminal repeat (ITR) sequences.
31. 31. The rAAV vector of claim 30, wherein the expression construct is flanked by two AAV ITRs.
32. The rAAV vector of claim 30 or 31, wherein the AAV ITR is an ITR of an AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAVrh8, AAVrh8R, AAV9, AAV10, AAVrhlO, AAV11, AAV12, AAV2R471A, AAV DJ, caprine AAV, bovine AAV, or mouse AAV serotype.
33. The rAAV vector according to any one of claims 30 to 32, wherein the AAV ITR is an AAV2 ITR.
34. The rAAV vector of any one of claims 30 to 33, further comprising a stuffer nucleic acid.
35. The rAAV vector of claim 34, wherein the stuffer nucleic acid is positioned upstream or downstream of the nucleic acid encoding the RNAi.
36. The rAAV vector of any one of claims 30 to 35, which is a self-complementary rAAV vector.
37. 37. The rAAV vector of claim 36, comprising a first nucleic acid sequence encoding an RNAi and a second nucleic acid sequence encoding a complement of the RNAi, wherein the first nucleic acid sequence is capable of intrastrand base pairing with the second nucleic acid sequence over most or all of its length.
38. 38. The rAAV vector of claim 37, wherein the first nucleic acid sequence and the second nucleic acid sequence are linked by a mutated AAV ITR, the mutated AAV ITR comprising a deletion of the D region and comprising a terminal resolution sequence mutation.
39. A cell comprising the rAAV vector of any one of claims 29 to 38.
40. A recombinant AAV particle comprising the rAAV vector according to any one of claims 29 to 38.
41. AAV virus particles include AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAVrh8, AAVrh8R, AAV9, AAV10, AAVrh10, AAV11, AAV12, AAV2R471A, AAV2 / 2-7m8, AAV DJ, AAV2 N587A, AAV2 E548A, AAV2 N708A, AAV V708K, AAV2-HBKO, AAVDJ8, AAVPHP. B. AAVPHP.
41. The rAAV particle of claim 40, comprising a capsid of rAAV2 / HBoV1 serotype, eB, AAVBR1, AAVHSC15, AAVHSC17, caprine AAV, AAV1 / AAV2 chimera, bovine AAV, or murine AAV capsid.
42. The ITRs and the capsid of rAAV viral particles are derived from the same AAV serotype 42. The rAAV particle of claim 40 or 41.
43. 42. The rAAV particle of claim 40 or 41, wherein the ITRs and the capsid of the rAAV virus particle are derived from different AAV serotypes.
44. The rAAV particle of claim 43, wherein the ITRs are derived from AAV2 and the capsid of the rAAV particle is derived from AAV1.
45. A composition comprising an rAAV particle according to any one of claims 40 to 44.
46. 46. The composition of claim 45, further comprising a pharma- ceutically acceptable carrier.
47. A kit comprising the RNAi according to any one of claims 1 to 17.
48. A kit comprising an AAV particle according to any one of claims 40 to 44.
49. 47. A kit comprising the composition of claim 45 or 46.
50. The kit of any one of claims 47 to 49, further comprising instructions for use.
51. 1. A method for treating a neurodegenerative synucleinopathic disease in a mammal, comprising administering to the mammal an RNAi comprising a first strand comprising a first nucleic acid having at least about 90% identity to the sequence 5'-UGCUCUUUGGUCUUCUCAGCC-3' (SEQ ID NO:24) or a first strand comprising a first nucleic acid having at least about 90% identity to the sequence 5'-UGGGCACAUUGGAACUGAGCA-3' (SEQ ID NO:8), and a second strand comprising a second nucleic acid.
52. 52. The method of claim 51, wherein the second nucleic acid comprises a nucleic acid having at least about 90% identity to the sequence 5'-GGCUGAGAACCAAAGAGUA-3' (SEQ ID NO:53) or a nucleic acid having at least about 90% identity to the sequence 5'-E1 passenger-3' (SEQ ID NO:37).
53. 1. A method for treating a neurodegenerative synucleinopathic disease in a mammal comprising administering to the mammal an RNAi comprising a first strand comprising a first nucleic acid having at least about 90% identity to the sequence 5'-UGCUCUUUGGUCUUCUCAGCC-3' (SEQ ID NO:24) and a second strand comprising a second nucleic acid having at least about 90% identity to the sequence 5'-GGCUGAGAACCAAAGAGUA-3' (SEQ ID NO:53), or a first strand comprising a first nucleic acid having at least about 90% identity to the sequence 5'-UGGGCACAUUGGAACUGAGCA-3' (SEQ ID NO:8) and a second strand comprising a second nucleic acid having at least about 90% identity to the sequence 5'-UGCUCAGUCAAUGUGCCUA-3' (SEQ ID NO:37).
54. 1. A method for inhibiting expression of alpha-synuclein in a mammal having a neurodegenerative disease, comprising administering to the mammal an RNAi comprising a first strand comprising a first nucleic acid having at least about 90% identity to the sequence 5'-UGCUCUUUGGUCUUCUCAGCC-3' (SEQ ID NO:24) or a first strand comprising a nucleic acid having at least about 90% identity to the sequence 5'-UGGGCACAUUGGAACUGAGCA-3' (SEQ ID NO:8), and a second strand comprising a second nucleic acid.
55. 55. The method of claim 54, wherein the second nucleic acid comprises a nucleic acid having at least about 90% identity to the sequence 5'-GGCUGAGAACCAAAGAGUA-3' (SEQ ID NO:53) or a nucleic acid having at least about 90% identity to the sequence 5'-UGCUCAGUCAAUGUGCCUA-3' (SEQ ID NO:37).
56. 1. A method for inhibiting expression of alpha-synuclein in a mammal having a neurodegenerative disease comprising administering to the mammal an RNAi comprising a first strand comprising a first nucleic acid having at least about 90% identity to the sequence 5'-UGCUCUUUGGUCUUCUCAGCC-3' (SEQ ID NO:24) and a second strand comprising a second nucleic acid having at least about 90% identity to the sequence 5'-GGCUGAGAACCAAAGAGUA-3' (SEQ ID NO:53), or a first strand comprising a first nucleic acid having at least about 90% identity to the sequence 5'-UGGGCACAUUGGAACUGAGCA-3' (SEQ ID NO:8) and a second strand comprising a second nucleic acid having at least about 90% identity to the sequence 5'-UGCUCAGUCAAUGUGCCUA-3' (SEQ ID NO:37).
57. 57. The method of any one of claims 51 to 56, wherein the first strand comprises a nucleic acid sequence having the sequence of SEQ ID NO:24 or a nucleic acid having the sequence of SEQ ID NO:
8.
58. 57. The method of any one of claims 52, 53, 55, or 56, wherein the second strand comprises a nucleic acid having the sequence of SEQ ID NO:53 or a nucleic acid having the sequence of SEQ ID NO:
37.
59. The method of any one of claims 51 to 58, wherein the first strand and the second strand are linked by an RNA linker capable of forming a loop structure.
60. 60. The method of claim 59, wherein the RNA linker comprises 4 to 50 nucleotides.
61. 61. The method of claim 59 or 60, wherein the loop structure comprises 4 to 20 nucleotides.
62. The method of any one of claims 59 to 61, wherein the RNAi comprises, from 5' to 3', a second strand, an RNA linker, and a first strand.
63. 62. The method of any one of claims 59 to 61, wherein the RNAi comprises, from 5' to 3', a first strand, an RNA linker, and a second strand.
64. The method of claim 63, wherein the RNAi comprises a nucleic acid sequence of SEQ ID NO:61 or SEQ ID NO:
63.
65. 65. The method of claim 64, wherein the RNAi comprises a nucleotide sequence that is about 90% identical to the nucleotide sequence of SEQ ID NO:61 or SEQ ID NO:
63.
66. The method of any one of claims 51 to 65, wherein the RNAi is encoded by an expression construct.
67. The method of any one of claims 51 to 66, wherein the nucleic acid encoding the RNAi comprises a miRNA scaffold.
68. The method of any one of claims 51 to 67, wherein the nucleic acid encoding the RNAi is operably linked to a promoter.
69. 69. The method of claim 68, wherein the promoter is capable of expressing the RNAi in the mammalian brain.
70. 70. The method of claim 69, wherein the promoter is selected from a cytomegalovirus (CMV) immediate early promoter, an RSV LTR, an MoMLV LTR, a phosphoglycerate kinase-1 (PGK) promoter, a simian virus 40 (SV40) promoter, a CK6 promoter, a transthyretin promoter (TTR), a TK promoter, a tetracycline responsive promoter (TRE), an HBV promoter, a hAAT promoter, an LSP promoter, a chimeric liver specific promoter (LSP), an E2F promoter, a telomerase (hTERT) promoter; a cytomegalovirus enhancer / chicken beta-actin / rabbit beta-globin (CAG) promoter, an elongation factor 1-alpha promoter (EF1-alpha) promoter, and a human beta-glucuronidase promoter.
71. 71. The method of any one of claims 68 to 70, wherein the promoter is a hybrid chicken β-actin promoter (CBA) comprising a CMV enhancer and a chicken β-actin promoter.
72. The method of any one of claims 66 to 71, wherein the expression construct further comprises an intron.
73. 73. The method of claim 72, wherein the intron is a CBA intron.
74. 73. The method of claim 72, wherein the intron is a chimeric intron.
75. 75. The method of claim 74, wherein the expression construct is a self-complementary vector and the intron is a delta-chimeric intron.
76. The method of any one of claims 66 to 75, wherein the nucleic acid further comprises a polyadenylation signal.
77. 77. The method of claim 76, wherein the polyadenylation signal is a bovine growth hormone polyadenylation signal.
78. The method of any one of claims 66 to 77, wherein the expression construct is encoded by a vector.
79. 79. The method of claim 78, wherein the vector is a recombinant adeno-associated virus (rAAV) vector.
80. 80. The method of claim 79, wherein the expression construct is flanked by one or more AAV inverted terminal repeat (ITR) sequences.
81. 81. The method of claim 80, wherein the expression construct is flanked by two AAV ITRs.
82. The method of claim 80 or 81, wherein the AAV ITR is an ITR of an AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAVrh8, AAVrh8R, AAV9, AAV10, AAVrhlO, AAV11, AAV12, AAV2R471A, AAV DJ, caprine AAV, bovine AAV, or murine AAV serotype.
83. The method according to any one of claims 80 to 82, wherein the AAV ITR is an AAV2 ITR.
84. The method of claim 83, wherein the rAAV vector comprises, from 5' to 3', an AAV2 ITR, a promoter, an intron, a nucleic acid encoding RNAi, a polyadenylation signal, and an AAV2 ITR.
85. 85. The method of claim 84, wherein the promoter is a CBA promoter.
86. 85. The method of claim 84, wherein the intron is a chimeric intron, a delta-chimeric intron or a truncated chimeric intron.
87. 87. The method of claim 86, wherein the chimeric intron is a CBA+ rabbit beta globulin intron.
88. The method of any one of claims 84 to 87, wherein the polyadenylation signal is a bovine growth hormone polyadenylation signal.
89. The method of claim 83, wherein the rAAV vector comprises, from 5' to 3', an AAV2 ITR, a CBA promoter, a chimeric intron, a nucleic acid encoding an RNAi, a bovine growth hormone polyadenylation signal, and an AAV2 ITR.
90. 90. The method of claim 89, wherein the vector further comprises a stuffer nucleic acid.
91. 91. The method of claim 90, wherein the stuffer nucleic acid comprises intron 1 of the human A1AT gene.
92. The method of any one of claims 79 to 91, wherein the vector is a self-complementary vector.
93. 93. The method of claim 92, wherein the vector comprises a first nucleic acid sequence encoding an RNAi and a second nucleic acid sequence encoding a complement of the RNAi, the first nucleic acid sequence being capable of intrastrand base pairing with the second nucleic acid sequence over most or all of its length.
94. 94. The method of claim 93, wherein the first nucleic acid sequence and the second nucleic acid sequence are linked by a mutated AAV ITR, the mutated AAV ITR comprising a deletion of the D region and comprising a terminal resolution sequence mutation.
95. The method of any one of claims 79 to 94, wherein the vector is encapsidated in a rAAV particle.
96. AAV virus particles include AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAVrh8, AAVrh8R, AAV9, AAV10, AAVrh10, AAV11, AAV12, AAV2R471A, AAV2 / 2-7m8, AAV DJ, AAV2 N587A, AAV2 E548A, AAV2 N708A, AAV2 V708K, AAV2-HBKO, AAVDJ8, AAVPHP. B. AAVPHP. eB, AAVBR1, AAVHSC15, AAVHSC17, caprine AAV, AAV1 / AAV2 chimera, bovine AAV, murine AAV, or rAAV2 / HBoV1 serotype.
96. The method of claim 95, comprising a capsid.
97. The method of claim 95 or 96, wherein the ITRs and the capsid of the rAAV viral particle are derived from the same AAV serotype.
98. The method of claim 95 or 96, wherein the ITRs and the capsid of the rAAV viral particle are derived from different AAV serotypes.
99. The method of any one of claims 95 to 98, wherein the rAAV viral particle comprises an AAV2 capsid.
100. 100. The method of claim 99, wherein the rAAV viral particle comprises an AAV1 capsid and the vector comprises an AAV2 ITR.
101. The method of any one of claims 51 to 100, wherein the rAAV particles of any one of claims 95 to 100 are in the form of a composition.
102. 102. The method of claim 101, wherein the composition further comprises a pharma- ceutically acceptable carrier.
Citation Information
Patent Citations
Compositions and methods for inhibition of snca
WO2012027713A2
